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ABSTRACT 
Respiratory syncytial virus (RSV) is the leading cause  of lower respiratory tract 
disease in children, and a significant source  of morbidity and  mortality among those 
susceptible, including infants, the elderly, and those with chronic lung diseases. Severe RSV 
infection during infancy is highly corelated with asthmatic symptoms later in life, suggesting 
a chronic alteration  of the pulmonary immune environment even after viral clearance. 
Within the airways,  dendritic cels (DCs) drive innate and adaptive immune responses to 
pathogens through the production of proinflammatory cytokines and the activation of T cel 
responses. Autophagy, a pathway that sequesters intracelular material within double-waled 
vesicles for  degradation  by lysosomes, enhances Tol-like receptor-dependent activation, 
cytokine  production, and antigen  presenting cel function  within  RSV-infected  DCs. Of 
interest, key  proteins that  orchestrate autophagosome formation are targeted  by  SIRT1, a 
NAD+-dependent histone and protein deacetylase. SIRT1 impacts many areas of biology and 
pathophysiology, including immune function. However, the role  of  SIRT1 in  DC  biology 
and its subsequent impact on adaptive immunity has not been elucidated. 
We have demonstrated that SIRT1 regulates DC activation and autophagy-mediated 
proceses  during  RSV infection, and that the absence  of  SIRT1 activity alters the antiviral 
immune response through the regulation  of innate cytokine  production. Upon infection, 
SIRT1 inhibitor (EX-527)-treated DCs, Sirt1 siRNA-treated DCs, or DCs from conditional 
knockout (Sirt1f/f-CD11c-Cre+) mice failed to  upregulate autophagy and cytokine 
production, but retained the capacity to present antigen to T cels. Additionaly, RSV 
infection  of Sirt1f/f-CD11c-Cre+ mice resulted in altered lung and lymph  node cytokine 
responses, leading to exacerbated pathology. Overal, these studies highlight the esential role 
of  SIRT1-mediated  DC cytokine  production in fine-tuning the antiviral adaptive immune 
response, and establish SIRT1 as a promising therapeutic target for the prevention of severe 





Human respiratory syncytial virus (RSV), a  non-segmented  negative-sense single-
stranded enveloped RNA virus of the Paramyxoviridae family, is a  ubiquitous  human 
pathogen. It  was first isolated from chimpanzes in the  1950s and subsequently recovered 
from severely il infants with lower respiratory tract (LRT) disease.1, 2 As the leading global 
cause of lower respiratory tract infection (LRTI) among infants and young children, RSV is 
also responsible for significant  morbidity and  mortality among the young, the elderly, the 
immunocompromised, and those  with chronic respiratory  diseases.3-5 Treatment  of  RSV 
infection relies heavily on supportive care, and despite decades of research eforts, no efective 
pharmacologic therapies exist.6 Even with the knowledge from extensive studies  on 
epidemiology, clinical course, diagnostic techniques, and animal models, the immunobiology 
of severe RSV infection is not fuly understood. Deeper questioning of this virus’s efect on 
the imune system is highly waranted to bring about therapeutic strategies aimed at severe 
pathology prevention and viral vaccine development. 
Respiratory Syncytial Virus (RSV) 
Virology & mechanisms of immune evasion 
RSV’s  RNA genome  of  10 genes encodes 11  proteins, including structural and 
envelope  proteins. The viral envelope contains three transmembrane proteins: fusion (F) 
glycoprotein, G glycoprotein (G), and a smal  hydrophobic  protein (SH). The  G  protein 
mediates host cel atachment while the F protein is responsible for fusion, cel entry, and the 
formation of the characteristic multinucleated epithelial cels, or syncytia.7 Only the F and G 
proteins induce  neutralizing antibodies, thereby  making these  proteins the  most important 
determinants of viral pathogenicity.8, 9 Five structural proteins compromise the remainder of 
the viral genome: a large RNA polymerase protein (L), nucleoprotein (N), phosphoprotein 
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(P), matrix  protein (M), two matrix  protein variants from alternate reading frames caled 
transcription procesivity factors (M2-1 and M2-2,) and two non-structural proteins (NS2, 
NS2). The  M proteins asemble  underneath the envelope,  while the  L, M2,  N, and P 
proteins asociate with the single-stranded RNA (Figure 1.1). 
Figure 1.1: Human respiratory syncytial virus. sRNA genome (A) and virion structure (B).10, 11 
RSV-G binds glycosoaminoglycans  present  on the apical surface  of target cels,12, 13 
while the  F  protein  binds  nucleolin,  mediating the fusion to the  host  membrane and the 
release  of nucleocapsid into the host cytoplasm.14, 15 Upon entry, the  L  protein initiates 
transcription (3’ to  5’) of the  negative-sense  RNA.16-18 Consequently, subgenomic  mRNAs 
are produced, with relative protein abundance determined by proximity to the 3’ end of the 
viral genomic RNA.16 During virion asembly, the nucleocapsid localizes at the host’s plasma 
membrane, which now expreses viral envelope proteins. New virions bud of of the apical 
surface  of  polarized alveolar epithelial cels, forming clusters  of long, fragile filaments that 
extend from the cel surface.19 
RSV primarily targets respiratory epithelial cels, particularly those that are ciliated, as 
wel as the intraepithelial immune cels lining the airways.20 In contrast to influenza virus, 
RSV induces scant cytopathology,20-22 perhaps due to its ability to  delay  programmed cel 
death or apoptosis of host cels. RSV infection induces the upregulation of numerous genes 
encoding inhibitors of apoptosis, such as the Bcl-2 family member myeloid cel leukemia-1.23 
Other  probably anti-apoptotic  mechanisms employed  by  RSV include p53 inhibition via 
Akt/Mdm2-mediated p53 degradation24 and increased levels of prosurvival sphingolipid SP1 
via enhanced ceramidase/sphingosine  kinase activity.23, 25 Moreover, it  has  been shown that 
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NS1, NS2, and SH RSV proteins facilitate viral replication, and thus higher viral titers, by 
suppresing premature apoptosis.26 
RSV reinfections are common throughout life, suggesting that protective immunity 
is incomplete and short-lived.7 This is likely in part due to the virus’s numerous mechanisms 
to evade or sabotage the host immune response.27 RSV-F protein binds Tol-like receptor 4 
(TLR4),  upregulating its surface expresion and sensitizing respiratory epithelial cels to 
endotoxin.28 Reports  have shown an increase in the  number  of  TLR4+ peripheral  blood 
monocytes in some infants  with  RSV bronchiolitis,29 but the role  of  TLR4 in vivo is  not 
clear.30 RSV’s NS1 and  NS2 proteins  have  been shown to interfere  with type I interferon 
(IFN) production, contributing to poor viral clearance and a skewed Th2 immune response.9 
The  G  protein is  heavily glycosylated, a  modification that interferes with antibody 
recognition.31, 32 RSV-G exists as both a ful-length membrane-bound form and a truncated 
secreted form (RSV-Gs), the later of which may act as a decoy for neutralizing antibodies.27 
In addition, the G protein contains a CX3C motif, which endows it with the ability to signal 
through the fractalkine CX3CR1 receptor and alter the chemotactic activity of leukocytes.33 
Whether this augments celular recruitment to the lungs during RSV infection or inhibits the 
function of endogenous fractalkine is unclear.9 Lastly, the conserved cysteine-rich region of 
RSV-Gs acts as a  potent  TLR antagonist in vitro, antagonizing  TLR2,  TLR4, and TLR9-
mediated inflammatory cytokine production.34 
Interestingly, studies suggest that  RSV-G  protein  has greater  potential than  RSV-F 
protein to  downregulate celular responses. For example, sensitization  of  mice  with 
recombinant vaccinia virus expresing the  RSV  G  protein folowed  by subsequent RSV 
chalenge primarily activated a Th2 response (alergy-like) with eosinophilia, while priming 
with RSV-F protein activated a Th1 response (antiviral) with lung inflammation.35 Similarly, 
human RSV-G-specific  T-cel lines  produced interleukin (IL)-4 and IL-10 in response to 
RSV stimulation,  whereas  F-protein-specific  T-cel lines produced Th1-dominated 
cytokines.36 
The virology of  RSV, in combination with the  host’s immune response and 
underlying health variables, contributes to the unique nature of RSV infection in the global 
human  population. With  no RSV vaccine available, it is vital to deeply ponder the 
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epidemiologic, environmental, genetic, and immunologic risk factors that  predispose 
individuals to severe RSV infection. 
Epidemiology & health burden 
The single  RSV serotype is clasified according to the  G  protein subgroups  A  or  B 
(RSV-A,  RSV-B).37, 38 As  with  other respiratory viral infections, the  prevalence  of each 
subgroup varies  by region and season,  with rates  of viral infection and  hospitalization 
peaking  between  mid-December and early  February.39, 40 No animal reservoirs exist, as 
humans are the  only  host for  RSV, yet the reasons for the near absence  of  RSV  between 
epidemics remain unclear.  
RSV is a  highly infectious,  universal  pathogen, such that every child experiences at 
least one RSV infection by the age of 2 years.41 While infections usualy pas in les than a 
week, they tend to  be  more severe in children aged  8 to  30  weeks.42 It  has  been estimated 
that on an annual basis the virus causes about 34 milion episodes of acute LRTI and nearly 
4  milion cases  of severe acute  LRTI requiring  hospitalization.4 Extrapolating from 
surveilance studies  of laboratory-confirmed  RSV infections to the entire  US  population, 
about two milion children under 5 years of age require annual medical atention for RSV 
infection,  with  ~3%  of them  being  hospitalized, another  25%  of them  being treated in 
emergency  departments, and the remaining  73%  being seen in  pediatric  practices.7 Every 
year at least 66,000 deaths worldwide in children under 5 years of age can be atributed to 
severe RSV infection, most commonly in developing nations.4 
Unfortunately, the total health burden  of RSV  disease is complicated by a strong 
relationship between infant  hospitalization  with  RSV infection and the  development  of 
recurent  wheezing and alergic asthma later in life.43-48 Studies involving Palivizumab, a 
monoclonal antibody to  RSV-F  protein that significantly reduces the severity  of  RSV 
bronchiolitis, further suggest a causal interaction  between  RSV infection and childhood 
asthma. Among cohorts  of “high-sick” children,  Palivizumab prevented  hospitalization for 
RSV  LRTI and decreased the incidence  of les severe  LRTI, thereby reducing the rate  of 
physician-documented recurent  wheezing at the age  of  3-4 years.49 Similar findings  have 
been reported where infants received prophylaxis with pooled immunoglobulins containing 
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high titers of RSV neutralizing antibodies.50 Furthermore, data derived from mouse models 
of viral-induced chronic lung  disease indicate lasting influences to the pulmonary immune 
milieu consistent with those observed in human asthmatics.51 These complications of severe 
RSV infection suggest that the  host antiviral immune response, as  wel as the immune-
mediated alteration  of the  pulmonary environment, facilitate the  development  of chronic 
airway disease.  
Unusualy,  RSV reinfection is common among young children,  with  most 
experiencing a decrease in symptom severity upon recurent exposure.52 While there is a low 
incidence  of  LRT involvement  upon reinfection in  older children and adults, the 
immunocompromised (e.g. transplant  patients) and the elderly  have a  higher risk  of 
developing severe  LRTI.3, 53 Likewise,  RSV greatly exacerbates  baseline  pulmonary 
dysfunction in patients with conditions such as asthma and chronic obstructive pulmonary 
disease (COPD).5 Overal, RSV infection contributes to extensive morbidity and mortality in 
these adult populations. 
Clinical manifestation & diagnosis 
RSV symptoms range from  mild  upper respiratory tract illnes  or otitis media to 
severe, life-threatening LRTI. The most common form of LRTI in RSV-infected infants is 
bronchiolitis, although pneumonia and croup are also observed. LRT signs, which lead to a 
clinical  diagnosis  of bronchiolitis, include tachypnea,  hyperinflation, retractions of the 
intercostal muscles, and inspiratory crackles and expiratory wheezing on auscultation. High 
fever is uncommon, while apnea may be observed in very young and premature infants.54 
Diagnosis  of acute  bronchiolitis is clinical,  based  on the  patient’s  presenting 
respiratory signs and symptoms,  posibly accompanied  by lethargy, iritability, and  poor 
feeding. While chest X-rays may show  hyperinflation and  patchy atelectasis,  helping to 
distinguish  bronchiolitis from  pneumonia, this tool is reserved for cases  of diagnostic 
uncertainty. Pulse  oximetry is recommended for al  patients reporting to the emergency 
department. Rapid antigen testing is routinely used for guiding cohort asignments, but its 
results rarely alter  management  decisions.54 Antigen  detection  by immunofluorescence and 
viral culture are common for confirming  RSV infection, but similar  methods are  not 
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available for al respiratory viruses. Hence, to investigate viral etiology for epidemiological 
studies, scientists  use reverse transcription-polymerase chain reaction (RT-PCR) for  RNA 
viruses and PCR for DNA viruses.7 
Etiology of RSV hospitalization & severe infection 
The risk factors for RSV-related hospitalizations and disease severity can be broken 
down into  host-related and virus-related. From the  host’s  perspective,  wel-established risk 
factors for hospitalization include pre-term birth, congenital heart or lung disease, acquired 
immunodeficiencies, interstitial lung disease, neuromuscular disease, liver disease, and inborn 
erors of metabolism.7 In spite of the aforementioned risk factors, at least half of al infants 
that report to the hospital with severe RSV infection are otherwise healthy.55, 56 Within this 
group, the most frequent and consistent risks include young age (< 6 weeks to < 6 months), 
male sex, presence of other children in the household, daycare atendance, tobacco exposure, 
lower family income, and lack of breast feeding.7, 57 Conversely, only two protective factors 
have been identified: Breast-feeding56, 58-61 and higher circulating levels of maternaly-derived 
neutralizing antibodies to RSV.62, 63 
Aside from these environmental and  health risk factors that contribute to 
hospitalization rates, many studies have identified a multitude of genetic susceptibility factors 
for severe RSV disease. Concordance studies  between  Danish  monozygotic and  dizygotic 
twin pairs revealed a modest (~20%) genetic contribution to the risk of hospitalization with 
RSV.64 Furthermore, studies  on the ethnic  background of RSV-infected  US infants  have 
shown that children of Native Alaskan or American Indian heritage are far more frequently 
hospitalized in comparison to the general US infant population,65, 66 while African ancestry 
was found to be protective against severe bronchiolitis compared to European ancestry.55, 67 
Genetic risk factors are further supported by the finding that during the same season a single 
RSV strain can cause variable severity  of  disease among the infected, ranging from  mild 
rhinitis to severe LRTI.64 
Analysis  of  347 single  nucleotide  polymorphisms (SNPs) from  hospitalized  RSV-
infected children identified the risk of severe RSV disease was predominantly asociated with 
innate immune genes, including VDR (vitamin D receptor), IFNA5 (interferon α5), NOS2A 
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(inducible nitric oxide synthase), and FCER1A (high-afinity IgE receptor α-subunit).68 
Further studies identified additional immune gene SNPs asociated with RSV disease severity 
in  preterm infants, such as IFNG (interferon gamma; risk enhancing), TGFBR1 
(transforming growth factor beta receptor 1; protective), and NFKBIA (nuclear factor kappa-
B 1A; protective).69 Surprisingly, polymorphisms in IL1RN (IL-1 receptor antagonist) were 
protective among  preterm infants, but disease enhancing among ful-term infants.69 
Examination  of the TLR4 gene has identified the overepresentation of two SNP variants 
among high-risk infants hospitalized with RSV compared to control infants,70 though these 
findings are not always consistent.68, 71 These data demonstrate that immunologicaly relevant 
receptor and signaling molecule genes contribute to host susceptibility to severe RSV LRTI. 
Additionaly, SNPs  within the  promoter- and coding-regions  of critical cytokines 
may be asociated with an increased risk of severe RSV disease. The role of Th2 cytokines, 
including IL-4, IL-5 and IL-13, in the immunopathology  of  human  RSV infection is 
controversial since some studies have found an asociation  between excesive  Th2 cytokine 
secretion and  disease severity,72, 73 while others  have reported litle  or  no  detection  of  Th2 
cytokines.74-76 Several studies reported overepresentation of common  SNPs  within the IL4 
gene, IL-4  promoter, and the IL-4 receptor alpha chain, among RSV-infected  hospitalized 
infants in comparison to  healthy controls.77-80 One wel-studied locus  on  human 
chromosome 5 (5q31) has been identified as a potential modifier of RSV disease severity.80 
This locus contains a cluster of cytokine genes, including the Th2 cytokine genes IL4, IL5, 
and IL13, as  wel as IFN regulatory factor  1 (IRF1), granulocyte-macrophage colony-
stimulating factor (CSF2), and  T-cel transcription factor-7 (TCF7). The  highest infant 
hospitalization odds-risk ratio involved several SNPs acros the IL-4 and IL-13 genes, among 
patients with  no  known risk factors for  RSV  disease.80 Future studies should investigate 
potential corelations between these haplotype-asociated gene  polymorphisms and RSV-
induced cytokine production. 
Lastly, SNPs within the genes of chemotactic cytokines have been studied in terms of 
risk for severe disease, since immune cels infiltrate the airways  during  RSV infection. For 
example, IL-8 atracts  neutrophils, and the chemokines RANTES/CCL5 and MIP-1α/ 
CCL3 recruit basophils, eosinophils, monocytes and T cels. While a polymorphism within 
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the IL8 promoter region was found to be overepresented in infants hospitalized with severe 
RSV  LRTI,81-84 subsequent studies  did  not find significant asociations  with  known  SNPs 
within the IL8 and IL-8 receptor genes.85, 86 However, evidence does support an increased 
risk among cariers of SNPs within CCL587-89 and its receptor, CCR5.72 
Viral factors contributing to the risk  of severe  RSV  disease include viral load, viral 
subgroup, and the presence of co-infection. There is some controversy over the extent viral 
load corelates  with  disease severity,  but studies suggest it  may  be age stratified and 
dependent  on  other risk factors, such as co-infection with another respiratory virus (e.g. 
parainfluenza, influenza, adenovirus, or rhinovirus).90, 91 Several human studies  have shown 
RSV-A asociated with higher disease severity compared to RSV-B, with the risk persisting 
after adjusting for age and  other risk factors.37, 38, 67 In vitro studies in  primary airway 
epithelial cels (AECs) and epithelial cel lines demonstrate that “prototypic” RSV-A strains 
are  beter at inducing nuclear factor-κB (NF-κB) activation and thus  pro-inflammatory 
cytokines (IL-6, IL-8) than RSV-B strains, supporting the clinical observations that RSV-A 
infections are more severe.92 Other studies have yielded clear evidence that individual RSV-A 
isolates  difer substantialy in their infectivity, virulence, and immunopathogenicity.93-97 
Overal, these findings  underline  how viral characteristics interact  with  host susceptibility 
factors to dictate disease phenotype. 
Taken together, the studies of risk factors contributing to RSV disease susceptibility, 
severity, and  hospitalization highlight fascinating corelations with the RSV-induced 
immune response.  However, most risk factor-disease relationships require investigation in 
much larger patient  populations, so that significance can  be atributed to the appropriate 
environmental, genetic, or viral risk factor involved in RSV pathology. 
Treatment, prophylaxis, and vaccination 
Management  of acute  bronchiolitis  upon  hospital admision largely consists  of 
supportive care, such as  nasal suction,  nasogastric  or intravenous fluids, supplemental 
oxygen, and nasogastric feeding. While it is common practice to administer bronchodilators 
(α and β adrenergics, anticholinergics, and  nebulized epinephrine), there is  no conclusive 
evidence that these positively impact disease outcome.54 Likewise, there is a lack of evidence 
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for the use of inhaled or systemic corticosteroids in treating severe bronchiolitis.98 One study 
showed that endogenous cortisol  production  during severe  RSV  bronchiolitis actualy 
suppresed cytokines  necesary for  mediating antiviral responses,99 suggesting that systemic 
corticosteroid treatment  may  not  be advisable in severe  RSV  disease.  Additionaly, inhaled 
corticosteroids during the acute phase of RSV infection did not show a preventative efect on 
post-infection wheezing.100 
The use of ribavirin, a FDA-approved antiviral agent used in nebulizer form to treat 
infants and children with severe bronchiolitis, is disputed. Meta-analysis indicates it may be 
efective in reducing  duration  of ventilation and length  of  hospitalization,  but the studies 
have been too smal in size and too variable to be conclusive.101 Curent AAP guidelines do 
not recommend ribavirin’s routine  use  due to these  uncertain studies, the  potential  health 
risk for caregivers (i.e. aerosolization of drug during administration), and the high cost, but 
reserve its use in high-risk infants with severe disease.54 
Palivizumab is a monoclonal antibody (RSV-F protein) prophylaxis for serious RSV-
induced  LRTI in  high-risk infants and young children. The  FDA-approved  dose is five 
monthly doses of 15 mg/kg body weight at the beginning of the regional RSV season. There 
is an international agreement that a ful course of the antibody should be given to premature 
infants  with a gestation age  <32  weeks,  but there is considerable variation in  US 
recommendations for use in infants at the gestational age of 32-35 weeks. While Palivizumab 
is efective in infants <35 weeks of age,102 providing such a prophylaxis to a population that 
comprises 3-5% of all annual births would be cost prohibitive. Thus, it is generaly reserved 
for <32 week-old premature infants and those born with cardiopulmonary complications.103 
Despite these imperfect treatments and prophylaxis for severe RSV infection, they are 
stil achievements given the absence of a RSV vaccine. Early atempts at vaccine development 
vividly  demonstrated just  how much the  host immune response contributes to RSV 
pathogenesis. The first formalin-inactivated (FI)  RSV vaccine (1960s)  not  only failed to 
provide antibody  protection,  but also  primed the infant  participants for enhanced  disease 
upon natural infection, such that 80% of the vaccinees required hospitalization and two even 
died.62 Initialy, it  was  hypothesized, given the link  between  RSV and  Th2-polarized 
wheezing, that the FI-RSV vaccine  had induced a  Th2 immune response, leading to 
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eosinophilia and the upregulation  of IL-4, IL-5, IL-13, and  posibly IL-10.104, 105 Re-
examination  of  post-mortem  histological specimens found few eosinophils, and instead 
reported immune complex deposition and neutrophilia in the lungs.105, 106 
The amplification of  RSV  disease  post-FI-RSV vaccine administration  has  been 
reproduced in  mouse, coton rat,  primate, and  bovine  models.107-110 Thus,  numerous 
alternative approaches to vaccine  development are  being tested, including live atenuated 
cold-pasaged and temperature-sensitive  mutants,111-113 recombinant  RSV virus  with 
deletions  of one  or  more virus  proteins,114 recombinant  RSV expresing host cytokines in 
order to boost vaccine responses,115, 116 vectored vaccines, and single virus protein subunit or 
peptide vaccines.117-119 Likewise, a variety  of adjuvants are being tested for their abilities to 
magnify the immunogenicity of vaccine preparations and to prevent vaccine-enhanced Th2-
skewing, some of which include  CpG  oligonucleotides and other TLR ligands.120 To  date, 
many of these vaccines and adjuvants have been shown to be highly protective in mice, but 
few have progresed to human testing. At the time of writing, 18 RSV vaccines, adjuvants, or 
combination therapies are curently in clinical trial (htps:/clinicaltrials.gov, search term: 
“RSV vaccine”). Therefore, a  beter  understanding  of  how  RSV interacts with the  host, 
especialy in terms of the aforementioned risk factors, must be achieved so that the road to 
RSV vaccine development is les replete with struggle. 
Primary immune response to RSV (in mice & men) 
Events  during the first  minutes and  hours after viral infection are  of paramount 
importance, not only in dictating the balance between viral replication and elimination but 
also in seting into  motion the subsequent adaptive (acquired) immune response. In 
particular, celular infiltrates and synthesized protein mediators must orchestrate a defense to 
clear the infection, while limiting injury to the surounding healthy tisue. Knowledge of the 
early and late phases of RSV infection has been gained from animal studies and analysis of 
human respiratory secretions and autopsy specimens. 
The most widely used animal models of RSV infection are inbred laboratory mouse 
strains, because of the ease of handling and housing, a wide variety of transgenic and knock-
out  models, and the availability of reagents.  However, they are semi-permisive  hosts, 
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requiring higher inoculum than  humans to elicit symptomatic infection (105-107 vs.  1000 
PFU (plaque forming units).121 Their lung anatomy is much simpler and the clinical signs of 
ilnes in  mice are rather  nonspecific, such as  weight los, lethargy, and rufled fur.  While 
acute RSV infection can cause airway obstruction and airway hypereactivity (AHR)122-125 as 
in  human infants, certain strains, such as  C57BL/6J mice,  do  not induce  AHR.93, 126 Peak 
viral load in the lungs of mice is seen 4-5 days post-infection (dpi) but becomes undetectable 
by plaque asay 8 dpi.125, 127 
Histopathology 
RSV-induced lung  pathology is characterized  by  bronchiolitis,  mucosal and 
submucosal edema, epithelial cel (EC) desquamation,  mucus  hypersecretion, as  wel as 
monocyte and granulocyte infiltration.128 The ECs, mucin, and immune cels along with the 
edema contribute to the dangerous obstruction of smal airways, especialy in infants. While 
the sloughing  of  ECs is generaly considered to reflect  necrosis,  markers  of apoptosis are 
abundant in  RSV-infected epithelium.129, 130 The celular infiltrate, consisting  mostly  of 
alveolar  macrophages and recruited  monocytes, is generaly peribronchiolar and often 
extending into the alveoli, while neutrophils are localized to the submucosa.128 
Detection of RSV by pattern recognition receptors (PRRs) 
Host-viral interactions are initiated via  host recognition  of  pathogen-asociated 
molecular paterns (PAMPs). This recognition occurs through patern recognition receptors 
(PRs) that are expresed on a wide aray of innate immune cels including alveolar epithelial 
cels (AECs),  dendritic cels (DCs),  macrophages, and  neutrophils. Several  PRR families, 
including Tol-like receptors (TLRs), RIG-I-like receptors (RLRs), and NOD-like receptors 
(NLRs), are involved in viral  detection. TLRs are  present  on the cel  membrane and in 
endosomes,  while RIG-I  helicases and  NLRs are intracelular  microbial sensors. The 
engagement of PRRs by PAMPs results in the activation of multiple signaling pathways and 
transcription factors such as NFκB and  members  of the interferon regulatory factor (IRF) 
family, which regulate the expresion  of inflammatory, immune, and antiviral genes that 
facilitate viral eradication.131 
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Membrane-bound TLRs implicated in the detection of RSV include TLR2, TLR3, 
TLR4, and TLR7.131 TLR2 is expresed in heterodimeric complexes with TLR1 and TLR6 
on the cel surface  of immune cels and  AECs, and recognizes a complex aray  of  proteins 
(bacterial and viral).132-135 While relatively litle is known about TLR2 in the context of RSV 
infection,  knock mouse studies  have shown that  RSV-induced TLR2/6 signaling promotes 
the  production  of tumor  necrosis factor alpha (TNFα), IL-6,  CCL2, and  CCL5.136, 137 On 
the  other  hand, TLR4, which forms as a  homodimer  on cel surfaces,  was the first PRR 
identified to  play a role in  RSV  detection.138 RSV-F  protein ligation  by  TLR4/CD14 
stimulates  NFκB-mediated innate cytokine  production.138 In  AECs,  RSV-induced  TLR4-
signaling increases TLR4 surface expresion and stimulates production of IL-6 and IL-8.28, 139 
Mice harboring a  nul  mutation in the Tlr4 gene failed to induce IL-6  production in 
response to RSV, and exhibited reduced NK cel traficking and function, such as decreased 
IL-12 production and impaired viral clearance compared to controls.138, 140 Two human gene 
polymorphisms within the extracelular domain of TLR4 have been corelated with increased 
risk of severe RSV bronchiolitis, especialy among high-risk infants.70, 141 Experiments using 
human bronchial ECs expresing one of the SNPs found reduced translocation eficiency of 
TLR4 to the cel surface, resulting in decreased NFκB-driven cytokine production and type I 
IFNs in response to stimulation.142 Conversely, in another study, TLR4 expresion on blood 
monocytes was positively corelated with disease severity.29 
TLR3 and  TLR7 are expresed  within intracelular compartments such as 
endosomes,  where they  detect  double-stranded (ds) or single-stranded (s) viral  RNA, 
respectively.131 Upon ligation of the dsRNA RSV replication intermediate, TLR3 recruits the 
adaptor protein  TRIF,  which activates IRF-3/NFκB driven production  of IFNβ and the 
chemokines  CCL5, IL-8, and  CXCL10.143 RSV infection  has  been shown to  upregulate 
TLR3 expresion in  human lung fibroblasts and epithelial cels.143, 144 While TLR3 did  not 
afect viral clearance in  mouse  models  of  RSV infection, it is important in modulating an 
antiviral  Th1 immune response.145 Tlr3 knockout (KO) mice  developed a  Th2-biased 
immune response  upon  RSV chalenge, resulting in increased IL-5 and IL-13 production, 
mucus secretion, and eosinophil infiltration into the airways.145 Similarly, TLR7 detects 
sRNA, thus activating NFκB and IRF-7 signaling in a MyD88-dependent manner to 
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mount host responses that  minimize immunopathology. RSV-infected Tlr7-deficient  mice 
experienced increased IL-4 production within the airways, in addition to IL-13 and IL-17, 
which promote  AEC  mucus secretion.146, 147 Interestingly,  DCs  derived from Tlr7-deficient 
mice preferentialy produced the Th17-promoting cytokine IL-23 at the expense of the Th1-
promoting cytokine IL-12, likely causing the elevated Th17 response upon RSV infection.146 
RLRs, expresed by cels such ECs and DCs, are intracelular PRRs that detect RSV-
derived  RNA upon  direct cel fusion. Retinoic acid-inducible gene I (RIG-I) binds  5’ 
triphosphate moieties on RNA, while melanoma diferentiation-asociated gene 5 (MDA-5) 
preferentialy recognizes long, stable  dsRNA.131 These  RLRs  bind viral  RNA with a 
conserved DEAD  box RNA-binding  helicase  domain, folowed  by interaction  of two N-
terminal caspase-recruitment  domains (CARDs)  with the  CARD  domain  of the 
mitochondrial membrane protein “IFNβ promoter stimulator 1” (IPS-1).148 This interaction 
leads to  dimer formation and subsequent activation  of IKKα/β-dependent NFκB signaling 
and TBK-1-dependent phosphorylation of IRF-3 and IRF-7, which trigger transcription of 
type I IFNs.149 RSV-infected Ips1-deficient  mice,  which are  unable to signal via  RLRs, 
produced very litle IFNβ, and exhibited a  Th1  phenotype  with  heightened airway 
neutrophilia and reduced viral clearance.150 RSV bronchiolitis has been shown to upregulate 
gene expresion  of several  PRs in infants, especialy RIGI, compared to those with  non-
RSV-induced bronchiolitis. Additionaly, these RSV-infected infants demonstrated a positive 
corelation  between RIGI mRNA levels and viral load.151 Finaly, RSV  NS1/2 proteins 
antagonize RLR signaling by blocking the interaction of RIG-I with IPS-1.152, 153 
 NLRs are specialized intracelular cytoplasmic sensors that recognize a wide aray of 
diferent PAMPS, including intracelular bacterial cel products and bacterial or viral nucleic 
acids.131 One  NLR implicated in  RSV  detection is NLRP3, yet the exact  mechanism  of 
interaction is unknown. Upon activation, NLRP3 recruits the adaptor protein ASC, forming 
large  multi-protein complexes caled inflammasomes, and leading to the  procesing and 
activation of pro-IL-1β and pro-IL-18 through the cysteine protease caspase-1.154-156 In one 
study, RSV infection in mouse bone marow-derived macrophages induced TLR2/MyD88-
dependent  upregulation  of pro-Il1b and Nlrp3 genes.157 When another NLR,  NOD2, 
recognizes RSV RNA, it rapidly translocates to the  mitochondrial surface to interact  with 
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IPS-1,  modulating IRF-3/NFκB-dependent IFN  production.131 The importance  of NOD2 
in  RSV  detection is evidenced  by impaired viral clearance, increased  weight los, increased 
proinflammatory cytokine and chemokine  production, and greater lung immunopathology 
in  RSV-infected Nod2-deficient  mice.158 Al together, these studies on  TLRs,  RLRs, and 
NODs ilustrate the importance of PRs in early detection of RSV and the development of 
robust innate immune responses to infection. 
Innate cytokine production & immune cel recruitment 
Upon  RSV infection, AECs signal their  distres by secreting a  wide variety  of 
proteins, most of which have been detected in lung tisue or bronchoalveolar lavage (BAL) 
fluid  of  RSV-infected  mice.7 These cytokines and chemokines include:  KC/CXCL1, 
MIG/CXCL9, IP-10/CXCL10, fractalkine/CX3CL1, MCP-1/CCL2, MIP-1α/CCL3, MIP-
1β/CCL4,  RANTES/CCL5, IL-6,  TNFα, IL-1α/β, and IFNα/β.121, 159, 160 In addition, 
resident alveolar macrophages are a key source of CCL3, CCL5, TNFα, IL-6 and IFNα in 
mouse  models  of  RSV infection.161-163 Proinflammatory cytokines, such as IL-1, IL-6, and 
TNFα upregulate the expresion of adhesion molecules, thereby facilitating the retention of 
recruited immune cels and  promoting their activation. Levels  of these innate proteins 
increase early during mouse infection, with BAL concentrations peaking at 24-48 hours post-
infection.124, 125 Concentrations  of IL-6 in the  BAL  positively corelate  with viral load and 
disease severity, suggesting it  may  promote  pathology at the later stages  of infection.125 
Controversy also surounds the role  of  TNFα in the clearance  of  RSV, as there are 
indications that it contributes to viral clearance  during the early stages  of infection  but 
promotes lung immunopathology later on.164-166 
During the initial phase of RSV infection, the rich, rapidly induced mixture of innate 
proteins atracts an army of immune cels into the airways. In mice, neutrophils are recruited 
as early as  24  hours  post-infection (hpi),95, 116, 122, 125, 167-169 although the  kinetics and 
magnitude of the response are RSV- and mouse-dependent.170 Natural kiler (NK) cels play 
a critical role in viral clearance during the early phase of RSV infection, with levels rising ~2 
dpi,  peaking  ~3-4  dpi, and  becoming  undetectable  by  8  dpi in  mice.104, 116, 171, 172 
Macrophages are always the  major cel type in the  BAL  of  mice, and  may  be further 
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upregulated by RSV infection, but the timing of recruitment varies by study.169 In contrast, 
eosinophils generaly represent a minor yet significant component of recruited immune cels 
in response to RSV,168, 173-175 although some studies report no significant diferences in their 
numbers between RSV-infected and control animals.20, 176, 177 
While there is an early transient rise in  neutrophils in  RSV-infected  mice, their 
recruitment is a predominant aspect of severe human RSV infection, making up 75-85% of 
the  BAL.178, 179 In a study  on RSV-infected,  mechanicaly ventilated infants, neutrophil 
numbers rose within the first few  days  of intubation and  declined thereafter.178 However, 
there  were lower  numbers  of recruited  neutrophils in the  BAL fluid  of  pre-term infants in 
comparison to ful-term infants. More variability has been seen in monocyte and lymphocyte 
proportions, perhaps  due to  diferences in the time  of sampling relative to the  onset  of 
symptoms.178, 179 Eosinophils are  detectable (<1% of  BAL) in a  minority  of  RSV-infected 
infants, although one study reported a subset  of infants exhibiting asthma-atack-like 
characteristics, with ~3% eosinophils in BAL fluid.180 
In  RSV-infected  mice, CD4+ T “helper” lymphocyte recruitment  begins early and 
plateaus ~4 dpi, while cytotoxic CD8+ T cel numbers rise sharply around day 4.104, 116, 161, 169 
Numbers  of  both  T cel subsets  begin to  decline  ~8  dpi,  but remain elevated in the lung 
through 20 dpi.7 Lymphocyte recruitment coincides with a second peak in the production of 
certain chemokines, including eotaxin,  CCL3, and  CCL5.124, 125, 160 At the  peak  of 
inflammation  ~7  dpi, a dense peribronchiolar and  perivascular infiltrate of  macrophages, 
lymphocytes, and some  neutrophils is  present.124, 181, 182 While  T cels constitute a smal 
fraction of BAL cels from severe RSV-infected infants (~2%), a significant increase in RSV-
specific CD8+ T cels does  occur in comparison to  uninfected controls.179, 183 Interestingly, 
significant numbers of CD8+ T cels were reported in the alveolar infiltrate of an infant with 
non-fatal RSV,128 suggesting a protective function of these cels, yet a second study of 9 fatal 
cases of RSV revealed a near absence of CD4+ and CD8+ T cels on autopsy.184 
Impresive numbers of dendritic cels (DCs) are recruited to respiratory mucosal sites 
of  both  RSV-infected  mice and  humans.  An increase  of monocyte-derived, “conventional” 
DCs (cDCs) and plasmacytoid  DCs (pDCs)  occurs in the lungs and lung-draining lymph 
nodes (LDLN) of RSV-infected mice.185-187 Similarly, a large influx of DCs is noted in nasal 
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washes  of  RSV-infected infants,  with  decreases in  both  DC subsets in  peripheral  blood 
compared to  healthy controls.188, 189 These antigen-presenting cels (APCs)  play an 
indispensable role in educating T cel  maturation and  diferentiation, and in  dictating the 
resultant immune environment  within the lungs. However,  under certain circumstances, 
DCs may be responsible for the inappropriate induction of aberant Th2-skewed responses 
to RSV, implicating these APCs as unfortunate mediators of RSV immunopathology. 
Pulmonary DCs: inducers of innate & adaptive immunity 
The lungs are continuously exposed to foreign threats, such as microbes, organic and 
inorganic dusts, man-made polutants, as wel as invading pathogens. As a result, a network 
of  DCs serves to recognize these foreigners, promote immune tolerance to innocuous 
particles, and activate the adaptive immune response in the case of pathogens. While AECs 
and macrophages expres PRRs, and can direct innate immunity through the production of 
inflammatory cytokines, DCs are special in that they transport pathogen-derived antigens to 
LDLN.190 Once here, these sentinel DCs stimulate naïve and RSV-reactive memory T cels 
through antigen-presentation, co-stimulation, and cytokine production. Efector CD4+ and 
CD8+ T cels then migrate to the lungs and clear viraly-infected cels.191 Thus, pulmonary 
DCs serve both the innate and adaptive arms of immunity. 
At steady state, three distinct  DC subsets reside in the lungs, al  of  which  perform 
unique tasks upon viral infection. CD11chigh CD103+ Langerin+ intraepithelial DCs, which 
expres the E-cadherin-binding integrin CD103 in mice (CD103+ DCs), intercalate with the 
epithelial lining of the respiratory tract and  project their celular  proceses into the airway 
lumen. CD11chigh B220+ CD11b+ DCs, expresing the integrin  CD11b (CD11b+ DCs), 
reside immediately  below the  basement  membrane in the lamina  propria. CD11b+ and 
CD103+ DCs are characterized as monocyte-derived/“conventional” DCs (cDCs), and 
corespond to the mDC1 (CD11c+ CD1c+) and mDC2 (CD11c+ CD141+) human subsets, 
respectively. Thirdly, CD11cdim CD11b- SiglecH+ plasmacytoid  DCs (pDCs) are found at 
steady state conditions, though their precise anatomical location is unknown. When the lung 
is chalenged  with a foreign invader, such as  RSV, additional  CD11b+ monocyte-derived 
cDCs (inflammatory DCs) are recruited into the conducting airways and lung parenchyma. 
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These  DCs are characterized by the surface expresion  of  CD11b, CD11c, Fc epsilon 
receptor (FcεRI), and the transiently expresed monocytic marker Ly6C.191 
DCs reside in a functionaly immature state in the  periphery  of the lung, but are 
poised to  detect  PAMPs such as viral  nucleic acids and  proteins.  Al lung  DC subsets are 
capable of being infected by RSV in vitro,192, 193 which results in their rapid maturation and 
the upregulation  of  both MHC clas proteins and the co-stimulatory  molecules CD40, 
CD80, CD83 and CD86.185, 194 UV-inactivated virus failed to stimulate DC maturation in 
several in vitro studies,195, 196 suggesting that a replicative virus is  necesary for complete 
activation. Once infected, human monocyte-derived  CD11b+ DCs  produce the  pro-
inflammatory cytokines IL-1β, IL-6, IL-12,  TNFα, and IFNγ, and chemokines such as 
CCL2, CCL3, CCL5, CXCL8, and CXCL10.197, 198 Additionaly, RSV-infected mouse bone 
marow-derived  DCs (BMDCs)  produce IFNα and IFNβ,  which are required for the 
upregulation  of co-stimulatory  molecules.199 Both  human and  mouse  pDCs  produce  high 
levels of IFNα folowing in vitro RSV infection. 193, 196 
Upon  RSV infection, the specialized immune functions of each  DC subtype likely 
originate from maturation-induced diferential PRR expresion, surface  protein expresion, 
antigen  procesing, and  T cel stimulation. The  upregulation  of surface expresion  of 
chemokine receptors CCR6 (ligands:  CCL20, β-defensin) and  CCR7 (ligands:  CCL19, 
CCL21) on cDCs enables their transport  of viral  RNA and  protein to LDLN for T cel 
presentation.191, 200 Migration  kinetics  difer by cDC subset, as numbers  of CD103+ DCs 
within the lungs decrease rapidly in the first 24 hpi, while the influx of inflammatory DCs 
results in an increased number of CD11b+ DCs in the lungs by 7 dpi.201 On the other hand, 
pDC  numbers  peak  by  3  dpi and  decrease  below baseline  by  8  dpi.185 CD103+ DCs are 
particularly eficient at the uptake of apoptotic epithelial cels, given their intimate proximity 
to the epithelium, and aided by their selective expresion of TLR3, CD36, and the C-type 
lectin Clec9A.202 These migratory CD103+ DCs are more potent in stimulating CD8+ T cels 
through cros-presentation  of antigens,  natural (viruses)202 and inorganic (labeled  beads).203 
In contrast, CD11b+ DCs selectively expres TLR2 and TLR7,202 and are major producers of 
chemokines that atract efector cels to the lungs  during infection.204, 205 CD11b+ DCs 
preferentialy activate  CD4+ T cels in the context  of severe influenza infection206 whereas 
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directly infected CD11b+ DCs indicate proficiency in priming CD8+ T cel responses.207, 208 
Les is  known about DC specialization  during  RSV infection, although ex vivo co-culture 
experiments suggest that RSV-infected CD103+ DCs and CD11b+ DCs proces RSV antigen 
equaly as wel, and are capable of stimulating both CD8+ and CD4+ T cels.201 
Despite the induction of DC maturation and the production of inflammatory innate 
cytokines, RSV reduces the capacity  of  DCs to stimulate  naïve T cels and induce their 
proliferation.185, 193, 195, 209 In  one  model, suppresion  of  T cel activation is  mediated  by an 
unidentified soluble factor produced  by  RSV-infected  DCs, in a  dose-dependent  manner, 
independently of IL-10, TGFβ, or T regulatory cels (Tregs).195, 210 This efect may be due to 
ligation of a combination of receptors to IFNα, IL-10 and IL-28.210 In a second model, RSV 
infection of DCs disrupts proper immune synapse formation between DCs and naïve T cels, 
such that T cels fail to polarize their Golgi to the cel surface, resulting in impaired T cel 
stimulation and proliferation.209 Studies have shown that these T cels subsequently entered 
an anergic state, becoming nonresponsive to proliferation signals such as IL-2 and anti-CD3 
antibody treatment and producing decreased levels of IL-2, IL-4, IFNγ, and TNFα.15, 195, 210 
This  phenomenon was only  observed in co-cultures  where the  DCs were infected  with 
replication-competent virus, as  naïve  T cels cultured  with  DCs incubated with UV-
iradiated RSV showed no proliferation defects.15 Similarly, memory T cels stimulated with 
RSV-infected  DCs showed  no  defects in efector cytokine  production  or proliferation, 
demonstrating that  RSV  only interferes  with  naïve  T cel stimulation.211 Thus,  perhaps a 
defect in the  DC-T cel interaction contributes to les robust primary responses to  RSV, 
increasing the likelihood of severe LRTI. 
Immaturity of the infant immune system 
While the immune system  of  neonates and young infants is capable  of  producing 
adult-like responses under certain conditions, most often there are quantitative or functional 
deficiencies in their innate and adaptive immune responses.  Macrophage cytokine 
production is often atenuated in neonates and children as compared to adults, in part due to 
diminished expresion or upregulation of PRRs. Neonatal DCs are reduced in frequency and 
difer in subset distribution, compared to adult DCs. These DCs show signs of poor antigen 
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presentation and T cel stimulation, because of decreased expresion of MHC molecules, co-
stimulatory molecules, and inflammatory cytokines, particularly IL-12p70.212 
Interestingly,  neonatal  T cels  display extraordinary  plasticity, ranging from 
unresponsive to stimuli that  normaly elicit strong adult  T cel activity to  highly reactive 
under the appropriate stimuli. For the most part, however, CD4+ T cels are diminished in 
their capacity to produce both Th1 and Th2 cytokines especialy IFNγ, which does not reach 
adult levels  until around adolescence.213-215 However,  Th2 skewing is  not clearly shown in 
human infections  despite this low IFNγ production,212 although it is observed in  neonatal 
mouse and human responses to environmental alergens.216 Overal, neonates are capable of 
mature cytotoxic T lymphocytes (CTLs) responses to virus.212 
Neonatal  B cel antibody  production is  often  delayed in  onset,  decreased in  peak 
titers, and  diminished in  duration.217, 218 Additionaly, infant  B cels  undergo litle somatic 
hypermutation after antigen encounter,219 resulting in an antibody repertoire that  displays 
lower afinity and decreased heterogeneity.212 After about the age of 2 years, most severe RSV 
LRTI is restricted to the immunocompromised, highlighting the immaturity of the immune 
system as a key factor in the frequency of LRTI in infants during primary RSV infection. 
RSV-induced protective vs. pathologic immunity 
Induction  of antiviral immunity is a  double-edge sword.  On  one side, a virus, 
particularly if cytopathogenic, must  be rapidly cleared. Yet  on the flip side, exuberant 
inflammatory immune responses can damage tisue, leading to systemic ilnes or local organ 
damage. Lung DCs can set in  motion  protective  or  pathologic  RSV-induced immune 
responses depending on the cytokines they produce and their antigen-presenting interactions 
with  T cels.  The aforementioned  DC subsets  must  work in synergy to  promote efficient, 
swift viral clearance  with  minimal injury to  by-standing tisue. Alas, studies point out 
pathological roles for certain  DC subsets and  T cels,  highlighting the complexity  of the 
immune response to RSV infection. 
Although  pDCs are  poor APCs,196 studies suggest that they are critical sources  of 
IFNα,  pro-inflammatory cytokines, and chemokines  upon exposure to  RSV. RSV-infected 
human pDCs isolated from peripheral blood secrete innate cytokines and large amounts of 
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IFNα.193 In  RSV-infected  mice, a rise in  pDC  numbers appears to  be protective,  while 
depletion  of  pDCs prior to  RSV infection results in increased viral replication, prolonged 
AHR, enhanced lung inflammation, and mucus  hypersecretion.185, 196 Additionaly, T cels 
restimulated with anti-CD3 from infected, pDC-depleted mice produced increased mRNA 
and  protein levels  of  Th2-asociated cytokines IL-4, IL-5, and IL-13, as  wel as the  Th1 
cytokine IFNγ.185, 196 This suggests that pDCs may play a role in regulating Th2-asociated 
responses. However, as poor stimulators  of  T-cel  proliferation and their specialized 
production of IFNα, pDCs seem best oriented to an early antiviral response than toward the 
induction of an adaptive during RSV infection. 
As pulmonary cDCs are  beter equipped at stimulating CD4+ and  CD8+ T cels 
during  RSV infection, their role in mounting efective antiviral  Th1 responses is key to 
succesful viral clearance.190 Viral reduction and the eventual eradication  of  RSV infection 
depends  on the actions  of activated  T cels, however it is evident that both  T cel subsets 
contribute to immunopathology.182 220, 221 Clinical ilnes was significantly reduced after the 
depletion of CD4+ or CD8+ T cels during RSV infection in mice, and was esentialy absent 
after depletion of both T cel subsets.182 In another study, transfer of RSV-specific cytotoxic 
T lymphocytes (CTLs) to RSV-infected animals resulted in rapid, yet dose-dependent viral 
clearance, but led to the development of increased lung pathology.220, 221 Interestingly, while 
pasive transfer  of  both  CD4+ and  CD8+ T cels enhanced  neutrophil eflux from lungs  of 
infected mice, transfer of only CD4+ T cels was asociated with pronounced eosinophilia.220 
These data support the dual roles of T cels in viral clearance and pulmonary damage during 
RSV infection. 
Alas, evidence suggests that some cDC subsets may contribute to the production of 
Th2 responses and lung immunopathology  during  RSV infection in mice. Mouse and 
human infant studies note an influx  of monocyte-derived CD11b+ cDCs into the airways 
and LDLN during  RSV infection,185, 189, 199 which  may contribute to  overal inflammation 
and AHR in both  RSV and subsequent alergen chalenges.187, 205, 222 Blocking migration  of 
CD11b+ cDCs to the lungs  or LDLN protected mice against RSV-induced 
immunopathology, resulting in more robust Th1 responses and enhanced viral clearance200, 
223 Similarly, the addition  of  monocyte-derived DCs increased Th2 responses and lung 
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pathology RSV-infected mice.223-225 Thus, the presence and relative number of cDCs within 
the lungs may direct pathological responses to RSV. 
Given the dual capacity of DCs to promote and hinder antiviral innate and adaptive 
immune responses  during  RSV infection,  questions emerge surounding the intracelular 
mechanisms responsible for  dictating  DC function. From transporting viral antigen to 
LDLN, to the production of innate cytokines, DCs depend on RSV recognition via TLRs. 
One  proces that facilitates  delivery  of antigen to the endosomal TLRs (TLR3,  TLR7) is 
macroautophagy,  whereby cytosolic contents are enveloped in a  double-waled  membrane 
and  delivered to endosomes. By utilizing a conserved  pathway involved in celular 
equilibrium to eficiently deliver intracelular pathogen-derived nucleic acids and proteins to 
endosomal compartments, DCs can promptly produce the necesary cytokines and stimulate 
reactive  T cels via  MHC-II  presentation.  Ultimately,  DCs  direct efective viral clearance, 
and reestablish immune system homeostasis. 
Autophagy as an antiviral immune defense 
Autophagy is an ancient intracelular  membrane traficking  pathway  whereby 
cytoplasmic material is sequestered within double-waled vesicles, which degrade upon fusion 
with lysosomes. Autophagy evolved as a  mechanism  by which  unicelular  organisms could 
survive  periods  of  nutrient scarcity  by reabsorbing  macromolecules from autophagocytosed 
organeles and proteins.226 Overal, autophagy maintains celular metabolic equilibrium and 
promotes cel survival  during  physiological (aging,  diferentiation) and  pathological 
(infection, degeneration, cancer) stres conditions.227 Specificaly, the molecular machinery of 
autophagosome formation plays critical roles in innate immunity, including the clearance of 
cytoplasmic  pathogens,  delivery  of viral antigen to endosomal  TLRs, and the loading  of 
antigen  onto  MHC  molecules for  T-cel  presentation.228-230 Likewise, autophagy  modulates 
immune cel function and inflammatory responses.231 Lastly, signaling sensors  of 
endoplasmic reticulum (ER) stres, which activate the  unfolded  protein response (UPR) 
during pathogenic insult, can also activate autophagic flux in an atempt to restore celular 
homeostasis via removal  of  damaged  organeles (ER-phagy,  mitophagy) and 
unfolded/misfolded proteins.232 Colectively, the data suggest important immunomodulatory 
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roles for autophagy during viral infection,  whereby it  promotes innate immune responses, 
such as  APC function in  DCs,233 as  wel as adaptive immune responses, such as  T cel 
development and activation.234 
Autophagosomes: initiation to maturation 
The  proces  of autophagosome formation is  highly conserved among eukaryotic 
organisms, and the  pathway  was first elucidated in yeast studies.226 A family  of autophagy-
related (Atg) genes  orchestrates the initiation, elongation/closure, and  maturation  of 
autophagosomes (Figure 1.2). Autophagy is initiated during starvation upon the inhibition 
of the mammalian target of rapamycin (mTOR) and the activation of AMP-activated protein 
kinase (AMPK),  which  phosphorylates Atg1/ULK1 (yeast/human) and causes the 
translocation  of the Atg1/ULK1 complex to the ER.235, 236 While the  primary source  of 
autophagosomal membrane is thought to be the ER, some studies suggest that the membrane 
precursor can be from the mitochondria, the  Golgi apparatus, the  nuclear  membrane,  or 
even the  plasma  membrane.237 The  phosphorylated Atg1/ULK1 complex, serving as an 
initiation scafold, activates the  VPS34-containing clas III  phosphatidylinositol-3-OH 
kinase (PI3K) complex located on the ER surface (VPS34-PI3K), which includes the clas III 
PI3K VPS34, VPS15, Atg14/ATG14L, and Atg6/Beclin-1.235, 238 The VPS34-PI3K complex 
then  produces  phosphatidylinositol-3-phosphate (PIP3),  which recruits  DFCP1 and 
Atg18/WIPI family  proteins that initiate the extension  of source  membrane into  pre-
autophagosomal structures termed omegasomes.239, 240 
The elongation and closure  of this double-waled  membrane is  dependent  on two 
ubiquitin-like conjugation systems. One involves creation  of the  ATG5-ATG12 conjugate 
through actions of the E1-like ATG7 and the E2-like ATG10. This conjugate then forms a 
2:2:2 complex with ATG16L1 on the outer membrane of autophagic precursors.241, 242 Since 
the  ATG5-ATG5-ATG16L1 complex  disociates from the  membrane  upon closure, its 
protein members are frequently used as markers for early autophagosome formation.243 The 
second conjugation system,  which requires  ATG7 and the  E2-like  ATG3, cleaves and 
conjugates  Atg8/LC3 with  phosphatidylethanolamine (PE).  The  PE-conjugated Atg8 
homologs,  which in  mammals are  LC3A/B/C,  GABARAP,  GABARAPL1/2/3 (hereafter 
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refered to as LC3), are incorporated into the inner and outer membranes of the developing 
autophagosome.243 As  LC3-II (conjugated  LC3) stably asociates  with completed 
autophagosomes, it is commonly  used in  microscopic analysis  of autophagy  progresion.244 
Finaly, the closed autophagosome matures upon fusion with acidic lysosomal compartments 
via the recruitment of the SNARE protein Syntaxin 17.245 The hydrolase-rich environment 
within the now-formed autolysosome  degrades the autophagosome contents, as  wel as the 
inner autophagosomal membrane.226, 245, 246 
 
Figure 1.2: The life cycle  of  an  autophagosome. (A) mTOR and  AMPK regulate autophagy 
induction in mammals. In the presence of a stimulus, such as nutrient starvation or pathogen infection, 
ULK1 is  phosphorylated and activates the  VPS34-PI3K complex,  which contains Beclin-1.  These 
activated autophagy proteins asociate with precursor membrane, often from the ER, to form an isolation 
membrane around general cytoplasmic content or cargo targeted to the  phagophore  by SLRs. (B) 
Elongation and shaping of the autophagosome are controled by two ubiquitin-like conjugation systems 
producing: (1) ATG5/12/16L complexes and (2) PE-conjugated LC3-II, which is incorporated into both 
inner and  outer autophagosomal  membranes. Upon autophagosome closure,  ATG5/12/16L and  LC3 
(delipidated by ATG4) are recycled. (C) Autophagic cargo, along with the inner membrane, is degraded 
upon maturation as the autophagosome fuses with an acidified lysosome.228, 247 
Involvement of autophagy in celular homeostasis 
The physiologic functions of autophagy include: providing a cel-autonomous source 
of  macromolecules and energy  during times  of celular  metabolic crisis or  nutritional 
deprivation, prevention  of cel  death and senescence  due to the accumulation  of faulty 
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organeles and large protein aggregates,248 and serving as a cel death modality.249 Al cels rely 
on constitutive autophagy to cary out basal housekeeping, including removal of organeles, 
such as depolarized mitochondria, damaged from regular wear and tear.250 Autophagy is also 
necesary for  normal  development, as in the case  of hematopoietic stem cel (HSC) 
maintenance and function.251 However, when these day-to-day activities do not proceed as a 
result of dysregulated or dysfunctional autophagy, disease phenotypes emerge.252 In addition, 
studies have found intersections between autophagy and immunity.252 
Upon  nutrient starvation, several events  need to  occur  before autophagosome 
initiation can  proceed. In the resting state,  TAK1-binding  proteins (TABs)  2 and  3  bind 
Beclin-1 and repres its activity.253, 254 However, during starvation,  ULK1-mediated 
activation  of  VPS34-PI3K is accomplished  by the  phosphorylation and release  of  Beclin-1 
from its TAB inhibitors. BECN1-regulated autophagy protein 1 (AMBRA1), also activated 
by ULK1, along with Beclin-1, recruits E3 ubiquitin ligase TNF receptor-asociated factor 6 
(TRAF6).  TRAF6 then  ubiquitinates and stabilizes  Beclin-1 and  ULK1,255, 256 enabling the 
progresion of autophagosome formation. 
The requirement for autophagy in nutrient homeostasis is dramaticaly recognized in 
Atg5-/- or Atg7-/- neonatal  mice.  Although  pups are  born  with few  physical  defects and in 
predicted  Mendelian ratios, these autophagy-defective  mice die within 24  hours after 
birth.257, 258 Force-feeding can  prolong survival, and analysis  of  metabolites confirms that 
these neonates sufer from systemic amino-acid deficiency and decreased glucose levels.257, 258 
Interestingly, in cultured wild-type (WT) hepatocytes, protein degradation increases by 3% 
total protein/hour upon starvation, with most of the increase atributable to autophagy.257, 259 
Therefore,  under  periods  of acute starvation, autophagy is an indispensable stres response 
capable of temporarily restoring energy balance until nutrients are once again plentiful. 
Sensing nutritional deficiency due to competition by microbial invasion is likely one 
ancestral  danger signal that eukaryotes  used to  detect and eliminate  pathogens through 
autophagy. In support  of this concept, signaling  downstream  of amino acid starvation  has 
been asociated with antimicrobial autophagy in response to bacterial260 and viral infection261 
in modern day immune cels. Other immune-sensing systems, such as PRR signaling upon 
recognition  of  PAMPs and damage-asociated  molecular  patern (DAMPs), also integrate 
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with autophagy. For example, TLR4 signaling leads to  ubiquitylation  of Atg1/Beclin-1 by 
the TRAF6,262 releasing  Beclin-1 from its inhibitor Bcl-2. TRAF6 also activates  ULK1 
through  ubiquitylation255 and thereby controls two key pathways that lead to autophagy. 
DAMPs, such as  DNA complexes,263 ATP,264 and  high-mobility group  box  1  protein 
(HMGB1),265 also activate autophagy.  HMGB1  de-represes  Beclin-1  by  displacing Bcl-2, 
and can also activate autophagy extracelularly  by interacting  with its cel surface receptor 
RAGE (receptor for advanced glycation end  products).265 Signaling through the IL-1 
receptor266 and the IFNγ receptor267-269 by IL-1 and IFNγ also trigger autophagy in 
macrophages through interaction with TRAF6 or Beclin-1, respectively. In contrast, the Th2 
cytokines IL-4, IL-6, IL-10, and IL-13 can inhibit autophagy under certain circumstances.268, 
270, 271 These examples ilustrate the complex integration of autophagy with PRR and cytokine 
receptor signaling. 
Role of autophagy in human disease 
Autophagy and autophagy genes have been implicated in a broad spectrum of human 
health isues including neurodegeneration,272-274 cancer,275, 276 and inflammation and 
immunity.241 Two groups have identified novel mutations in WDR45/WIP14, a mammalian 
homologue of yeast  Atg18, in  patients  with  SENDA (static encephalopathy  of childhood 
with  neurodegeneration in adulthood).277, 278 In lymphoblastoid cel lines  derived from 
SENDA patients, researchers noted a severe reduction in WIP14 protein expresion and the 
accumulation of aberant autophagic ATG9A+ LC3+ (early stage) structures.278 Amongst the 
many genes implicated in Parkinson’s disease pathogenesis, a progresive neurodegenerative 
disorder, PARK2/Parkin and PARK6/PINK1 lead to autosomal recesive  or spontaneous 
juvenile-onset  Parkinson’s  disease.279, 280 PINK1 is a  mitochondria-asociated  protein  kinase 
that acts upstream of Parkin, an E3 ligase implicated in selective autophagy of mitochondria, 
or mitophagy.281, 282 Consistent  with this finding, excesive  mitochondrial  damage  has  been 
linked to Parkinson’s disease,283 suggesting that at least some forms of Parkinson’s disease are 
caused by the lack of autophagy to clear these accumulated, defective organeles. 
A connection between autophagy and cancer  has long  been  proposed. Early  on in 
cancer development, autophagy likely plays a preventive role, but once a tumor develops, the 
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cancer cells usurp autophagy for their own cytoprotection.284, 285 A key role for autophagy in 
controling the  unregulated cel growth  of tumor  development  has  been shown through 
studies of Atg1/BECN1. The protein Atg1/Beclin-1 interacts with the anti-apoptotic protein 
Bcl-2, which prevents Bax-dependent release of mitochondrial cytochrome c.286 Patients with 
a monoalelic deletion of BECN1 have an increased predisposition for human breast, ovarian, 
prostate, and colorectal cancers, as  wel as a poorer prognosis.252 Mutations in other 
autophagy proteins, such as ATG5 and UVRAG, are also corelated with the development of 
human cancers.252 
Finaly, given the evidence in support  of cels applying autophagic  machinery to 
promote antimicrobial responses, it is  of  no surprise that immune-mediated diseases  have 
also  been asociated with defective autophagy function. Genome-wide asociation studies  
(GWAS) on  non-synonymous  SNPs have linked ATG16L1 variants  with susceptibility to 
Crohn’s disease,287, 288 a major type of inflammatory bowel disease that can afect any portion 
of the  digestive tract. The  ATG16L1  protein  poseses a  C-terminal  WD repeat  domain, 
within which or immediately upstream lies the Crohn’s disease-asociated mutation, T300A 
(Ala197Thr). However, studies  have shown that this  WD  domain is  not esential for 
ATG16L1’s autophagic activity.241, 289, 290 While the exact contribution of the ATG16L1 
T300A mutation to human Crohn’s  disease  pathogenesis  has yet to  be clarified, Atg16l1 
mutant  mouse studies suggest some  posibilities. Atg16l1-deficient  macrophages  produced 
increased levels  of the inflammatory cytokine IL-1β and IL-18  upon lipopolysaccharide 
(LPS) stimulation.290 On the  other  hand, Atg16l1 hypomorphic mice exhibited aberant 
granule formation and ER stres in Paneth cels, which produce antimicrobial products and 
constitute a cardinal component  of the intestinal stem cel  niche.291 Another report stated 
that ATG16L1 poseses an immunosuppresive role during intestinal bacterial infection.292 
Apart from ATG16L, other autophagy-related proteins, including IRGM (immunity-related 
GTPase  M) protein,293, 294 NOD2,295, 296 autophagy-targeting factor  SMURF1,297 and 
ULK1298 are reported to contribute to Crohn’s disease. However, as some of these proteins 
hold  other  biological roles outside  of  promoting autophagy, it remains  uncertain  whether 
they relate to  Crohn’s  disease  pathogenesis via autophagy  modulation.252 Interestingly, 
population genetic analyses  have also linked an IRGM gene variant (IRGM-261T) with 
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susceptibility to tuberculosis299 and IRGM polymorphisms to systemic lupus erythematous 
(SLE).300 Moreover, GWASs have linked ATG5 variants with the development of asthma301, 
302 and a greater risk  of SLE.303, 304 Thus, autophagy shows clinical relevance as a result  of 
various genetic connections to neurodegenerative, cancerous, immunological, and 
inflammatory disorders. 
Host autophagy during infection by intracelular pathogens 
The antimicrobial functions of autophagy provide a series of bariers against invading 
microorganisms. This includes the  proces  of xenophagy, the selective  degradation  of 
intracelular  pathogens in  double-membrane autophagosomes.305 Secondly, LC3-asociated 
phagocytosis (LAP), which engages autophagic machinery, aids in expediting the degradation 
of  bacterium and  other extracelular  objects such as  TLR-ligand-coated  particles.306 LAP 
phagosomes are matured through the autophagic pathway, using Beclin-1-VPS34 complexes 
and  LC3 conjugation, resulting in robust  phagolysosomes.306-308 Thirdly, a group  of 
autophagic adaptors, known as sequestosome-1 receptors (SLRs), bind ubiquitinated bacteria 
and deliver them to autophagosomes via interactions with inner membrane-bound LC3.309-312 
Lastly, autophagy-asociated factors can directly bind target microbial proteins. For example, 
ATG5 binds the Shigela spp. surface  protein,  VirG,313 and along  with  ubiquitylation and 
SLR activity,309, 314 herds the bacteria to autophagosomes for elimination. 
Bacteria may also counteract or seize control  over host autophagic  machinery for 
their own benefit, highlighting the importance of autophagy in antibacterial defense. These 
inhibitory mechanisms include the expresion of proteins that interfere with autophagosomal 
targeting, formation, or maturation. For example, Listeria proteins AktA and InIK interfere 
with host  ubiquitin tags,310, 315 while Shigela protein IcsB  masks  bacterial epitopes,316 al  of 
which asist the  bacteria in evading recognition by autophagic  machinery. Salmonela sp. 
deubiquitinase SseL cleaves of ubiquitin tags to thwart SLR-mediated targeting to nascent 
autophagosomes.317 Some bacteria  directly “atack” autophagy  proteins, such as the 
Legionela virulence factor  RavZ, which causes ireversible  deconjugation  of Atg8 
homologs.318 Lastly, captured Listeria blocks autophagosomal acidification, and thus 
maturation, via the pore-forming protein listeriolysin O.319 
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Likewise,  host autophagy is important in curbing viral load, given the number  of 
viral  proteins that interfere  with or  utilize autophagic  machinery for their  own replication. 
The  herpes simplex virus  1 (HSV-1) virulence factor ICP34.5,320 influenza virus  M2 
protein,321 HIV  protein  Nef,322 murine γ-herpesvirus  68 M11 (BCL2  homologue),323 and 
KSHV vBcl-2324 al target  Beclin-1 to either  block autophagy  or inhibit autophagosomal 
maturation via lysosomal fusion. HIV-1  Nef, hepatitis C virus (HCV) NS3, and  measles 
virus  Mev3 interact  with IRGM,  which  has consequences yet to  be investigated.325 
Interestingly, some viruses utilize the autophagosomal machinery to  optimize their yield, 
including HCV, Dengue virus,  poliovirus,  Coxsackie  B virus, and  HIV.326 For example, 
poliovirus tethers together autophagosomes, which serve as scafolds for RNA replication and 
contribute to virion egres once viral particles within the cel reach a threshold level.327 
Autophagic regulation of immune cel function 
Autophagy functions as a  bulk transporter  of  proteins from the cytoplasm into the 
lumen of antigen-procesing compartments. As such, autophagy facilitates several aspects of 
DC  maturation in response to  pathogen  detection.  One, the  proces  helps load cytosolic 
peptides onto MHC-I and MHC-II proteins, which are subsequently presented to CD4+ or 
CD8+ T cels, respectively. Second, the delivery of cytoplasmic contents to endosomal TLRs 
enables surveilance of the intracelular environment, thereby facilitating the upregulation of 
innate cytokine  production, MHC-I/II expresion, and co-stimulatory molecule expresion 
that are vital to T cel activation during antigen presentation. The proces of autophagy may 
be especialy critical to the immediate detection of RSV, since the virus enters cels via non-
receptor-mediated endosomes.7 
A deficiency  of autophagy in  DCs can result in altered antigen-presentation in the 
context of MHC-I/II, leading to pathological T cel responses. In autophagy-deficient mice, 
both positive and negative selection of CD4+ T cels but not CD8+ T cels were afected.328 
Researchers transplanted Atg5-deficient thymi into WT mice, causing an infiltration  of 
autoreactive CD4+ T cels into multiple organs and the induction of autoimmune colitis.328 
This suggests that autophagy-enhanced MHC clas II presentation has a role in thymic T cel 
selection. Other studies  have shown that autophagy-dependent antigen  presentation is 
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defective in  DCs from  patients  with  Crohn’s  disease carying the ATG16L1 or NOD2 
disease risk variants.329 With regard to viral infection, DC presentation of the Epstein Bar 
virus (EBV)-encoded nuclear antigen 1 (EBNA1), a CD4+ T cel epitope found in healthy 
EBV cariers, requires autophagy.330, 331 Studies by  our laboratory  have  demonstrated that 
DCs upregulate autophagosome formation  upon  RSV  detection, and that autophagy 
facilitates  DC  maturation, cytokine  production, and antigen  presentation, and is thus 
required to stimulate IFNγ from RSV-reactive T cels.233 The contribution of autophagy to 
MHC-I cros presentation is not fuly understood, but it may contribute to the delivery of 
proteasome-degraded  peptides to  MHC-I-containing compartments.332, 333 Of  note, 
inhibition of ATG16L and IRGM expresion in human DCs leads to hyperstable interactions 
with  T cels and increases  T cel activation.334 Thus,  while autophagy initialy  promotes 
antigen procesing, at later stages it may help downregulate the response, such as through the 
disasembly of immunological synapses.334 
In addition to sequestering viral peptides for presentation to T cels, the transport of 
viral  nucleic acids to endosomal  TLRs via autophagy induces pro-inflammatory cytokine 
production in response to infection. This  was first established in  pDCs, where  ATG5  was 
necesary to enhance TLR7-dependent IFNα production in response to vesicular stomatitis 
virus (VSV).335 Human  pDC studies also demonstrated an autophagy-dependent IFNα 
production in response to HIV-1336 and the paramyxovirus Simian virus 5.337 Interestingly, 
macrophages or DCs treated with TLR ligands were reported to upregulate autophagosome 
formation, suggesting cooperation between  TLRs and autophagic  proteins in response to 
PAMPs. The upregulation of autophagy in macrophages was noted in response to agonists of 
TLR1/2, TLR3, TLR4, or TLR7.338 Treatment of M. tuberculosis-infected macrophages with 
TLR4 or TLR7 ligands increased bacterial kiling, suggesting that TLR-induced autophagy 
promotes intracelular  pathogen clearance.338 The  upregulation  of autophagy in advance  of 
microbial invasion  promotes the expresion and the  prompt delivery of antimicrobial 
peptides to lysosomes, and autophagosomal  proteins to forming phagophores, thereby 
expediting the eventual acidification  of  pathogen-laden autophagosomes.339-341 Therefore, 
enhanced recruitment of autophagy in response to TLR signaling positively modulates DC 
antigen presentation and cytokine production in response to antimicrobial infection.342, 343 
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Aside from its role in  APC function, autophagy afects  both the  homeostasis and 
activity of efector cels involved in adaptive immunity, including T cels and B cels. After 
exiting the thymus, naïve T cels rely on autophagy and mitochondrial content reduction for 
their  maturation.344 Calcium ions sequestered in  ER-like structures have  been  observed in 
ATG7-deficient  T cels, suggesting the  necesity  of autophagy for  ER  maintenance.345 
Autophagy is also  pro-survival in activated  T cels  by counteracting the  pro-apoptotic 
function  of  CD95 (FAS) and  CD95L (FASL),  which are  upregulated  by  TCR (T cel 
receptor) stimulation.346 While autophagy  may  not  be important for the survival  of  most 
mature  B cels,347 lymphoid  precursor stages are afected  by the absence  of autophagy.348 
Interestingly, the lack of autophagy leads to excesive immunoglobulin secretion by plasma 
cels, indicating the importance  of  ER  maintenance  during conditions  of  high secretory 
demand.349 Autophagy is also important for the preservation of the bone marow plasma cel 
pool, which is relevant for long-lived humoral immunity.349 Overal, autophagy plays crucial 
functions in both innate and adaptive immunity via influences on immune cel function. 
Modulation of inflammation by autophagy 
The recognition  of autophagy’s anti-inflammatory functions stemmed from the 
observed increase in IL-1β and IL-18 production in Atg16l1-/- mice with Crohn’s disease. 298, 
300 Several convergent reports show that autophagy  has a  negative role in inflammasome 
activation,350, 351 likely explaining the  observed cytokine  profile in Atg16l1-deficient  mice. 
Under sterile conditions, autophagy clears the cytoplasm  of  debris,  protein aggregates, and 
defective  organeles that could endogenously activate inflammasomes.  Yet if autophagy is 
blocked, this leads to the accumulation  of  depolarized mitochondria,  which leak 
inflammasome agonists such as  mitDNA and reactive  oxygen species (ROS). 350, 351 Studies 
with Atg5-/- macrophages have demonstrated how ROS in autophagy-defective cels activates 
both the inflammasome and the calpain  pathways (protease  which cleaves  pro-IL-1α) that 
lead to the exces  production  of IL-1β and IL-1α, respectively. In the context  of M. 
tuberculosis infection, this exces  of IL-1α leads to magnified and  prolonged  Th17 cel 
responses, which contribute to lung tisue damage in mice.352 However, during influenza A 
viral infection, the removal  of  damaged  mitochondria is  not  pasive. A NOS2-receptor-
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interacting serine/threonine protein kinase 2 (RIPK2) pathway activates ULK1 to maintain 
or increase  mitophagy, thereby reducing the set  point of inflammasomal activation.353 
Importantly, autophagy  may  downregulate  prolonged inflammasome activity  by removing 
aggregated inflammasomal components.256 Lastly, autophagy factors can degrade pro-
inflammatory signaling factors, such as BCL-10 complexes354 to reduce NFκB activation in 
antigen-activated  T cels.355 Therefore,  basal autophagy  protects cels from inadvertent 
inflammation via the elimination of microorganisms and endogenous iritants. 
Interactions between ER-stress, autophagy, & viruses 
Secreted and transmembrane proteins fold and mature in the endoplasmic reticulum 
(ER). However, ER homeostasis can be perturbed by physiological and pathological insults 
such as high protein demand, viral infections, environmental toxins, inflammatory cytokines, 
and mutant protein expresion, al of which lead to the accumulation of mis- and unfolded 
proteins. Three ER-bound proteins monitor conditions in the  ER lumen, sensing whether 
there is an insuficiency in protein folding capacity or a  depletion  of  ER calcium gradient: 
inositol-requiring protein 1α (IRE1α), activating transcription factor 6 (ATF6), and protein 
kinase-like  ER  kinase (PERK). These trigger the unfolded  protein response (UPR), an 
adaptive response aimed at restoring ER balance by three mechanisms: transcription of genes 
to increase folding capacity, transient reduction in  protein translation, and ER-asociated 
degradation (ERAD). In the case  of unresolvable, chronic ER stres, the  UPR initiates 
programmed cel death.356, 357 
ERAD easily removes and degrades accumulated, soluble  proteins via the 
proteasome, but its capacity is  overwhelmed  by protein aggregates and  damaged  organeles 
that  often result  during  ER stres. 358 In such cases, the  UPR has  been shown to activate 
autophagy to mediate celular survival.358-360 For example neuroblastoma cels treated with ER 
stresors  markedly induced the formation  of autophagosomes, as asesed  by microscopy, 
while inhibiting autophagy rendered cels vulnerable to  upregulated  ER stres.359 Most 
recently, a microaray analysis  of colon cancer cels subjected to  ER stres showed the 
transcriptional  upregulation  of autophagy receptor genes  SQSTMI/p62,  NRI, and 
BNIP3L/NIX.358 SQSTMI/p62 and  NBR1 are ubiquitin-binding  proteins with an  LC3 
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interacting region (LIR), which targets ubiquitinated substrates to the autophagosome.361, 362 
BNIP3L/NIX is an adapter for the removal of damaged/depolarized mitochondria,363 so the 
data indicate a role for mitophagy in protecting cels during ER stres by limiting apoptosis. 
IRE1α, the most conserved, sole branch in lower eukaryotes,364 is consistently observed as a 
major regulator  of this UPR-induced autophagic response.358, 359 Of  note, IRE1α’s 
ribonuclease activity unconventionaly splices an intron from mRNA encoding XBP1, which 
is translated into XBP1s, a transcription factor that mediates downstream IRE1α signaling.356 
 Viruses cause ER  disequilibrium as  wel as  hijack the  UPR to their advantage, in 
congruence  with their ability to commandeer the autophagy  pathway. For example, HCV, 
poliovirus, human cytomegalovirus (HCMV), and HSV-I strictly depend on the ER for viral 
asembly and  budding,365 and thus are able to  perturb host ER replication complexes, and 
ER  membrane for source-membrane.366 Viral proteins can induce  ER stres via their 
competition for ER-mediated glycosylation, such as during influenza A virus, hepatitis virus, 
and Japanese encephalitis virus (JEV) infection.367-369 In addition, the depolarization of ER-
calcium  diferentials by viral viroporin  proteins, such as the rotavirus  NSP4  protein370 and 
picornavirus 2B protein,371 can trigger ER stres. Recently, RSV infection has been shown to 
induce IRE-1α and ATF6 signaling, while IRE-1α inhibition enhanced viral replication.372 
 As discused, autophagy is critical in maintaining celular equilibrium and mediating 
stresor-induced inflammatory and immune responses, such as  during RSV infection. The 
fascinating relationships  between autophagy, the  UPR, and viral immunity are further 
intertwined when sirtuin 1 (SIRT1), a histone/protein deacetylase, is considered. Researchers 
have reported that three  ATG  proteins (ATG5,  ATG7,  ATG8/LC3) are  deacetylated and 
activated by SIRT1.373 Therefore, given the significance of DCs in dictating robust antiviral 
immune responses, and autophagy’s crucial role in traficking viral antigens to endosomal 
PAMPs, the exploration of SIRT1 activity within DCs is exceptionaly waranted to beter 
understand RSV-induced immunity. 
Sirtuin 1: a regulator of immune responses 
Sirtuins (SIRTs) are mammalian  homologues to the yeast  protein Sir2,374 and  were 
originaly  described as nicotinamide adenine  dinucleotide (NAD+)-dependent type III 
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histone deacetylases (HDACs). The deacetylation reaction converts NAD+ into nicotinamide 
(NAM), a feedback inhibitor, and generates 2’-O-acetyl-ADP-ribose and a  deacetylated 
protein substrate.375 However, several sirtuins are now known to perform additional catalytic 
functions, including  deacylation, demalonylation, and  desuccinylation (Table 1.1). 
Phylogenetic analysis reveals that the 7 mammalian sirtuins can be divided into four clases: 
Clas I, SIRT1-SIRT3; Clas II, SIRT4; Clas III, SIRT5; and finaly Clas IV, SIRT6-7.374 
While al sirtuins share a ~30 kDa core deacetylase domain, their N- and C-termini vary as 
wel as their subcelular localization, protein targets, and regulatory functions (Table 1.1). 
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Table 1.1: Properties  and functions  of  mammalian sirtuins. CPS1, carbamoyl  phosphate 
synthetase 1; CtIP, CtBP-interacting protein; FOXO, forkhead box O; GABP-β1, GA binding protein β1 
subunit; GCN5,  histone acetyltransferase  GCN5; GDH, glutamate  dehydrogenase;  HIF1α,  hypoxia-
inducible factor  1α;  HMGCS2,  3-hydroxy- 3-methylglutaryl  CoA synthase  2;  LCAD, long-chain acyl 
CoA  dehydrogenase; MCD,  malonyl  CoA  decarboxylase; NFκB,  nuclear factor-κB; NPM1,  nucleolar 
phosphoprotein  B23; OXPHOS,  oxidative  phosphorylation; PAF53,  polymerase-asociated factor  53; 
PAR3,  partitioning  defective  3  homologue; PARP1,  poly (ADP-ribose)  polymerase  1; PEPCK, 
phosphoenolpyruvate carboxykinase;  PGC1α, peroxisome  proliferator-activated receptor-γ co-activator 
1α; PPARα,  peroxisome  proliferator-activated receptor alpha; SDH, succinate  dehydrogenase; SOD1,2, 
superoxide dismutase 1,2. 376-378 
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The  most studied sirtuin,  SIRT1,  was first noted to  deacetylate  histones,  but 
thereafter shown to  poses a  wide aray  of targets, including  p53 and NFκB.379 It is a 
ubiquitous protein in the  body, and expresed in  neurons, heart, liver,  kidney,  blood and 
spleen, for example. SIRT1 impacts many areas of biology and pathophysiology (Figure 1.3). 
Like autophagy, it is induced in terms  of expresion and activity  by  nutrient  deficiency,380 
critical during cel stres survival,381-383 and implicated in various human health disorders.384-
386 In addition, recent studies have shown SIRT1 to regulate aspects of ER stres, including 
the  UPR.387-389 While  SIRT1 influences immunity  by regulating  proceses such as 
lymphocyte activation,  T-cel  proliferation and  diferentiation, and  macrophage cytokine 
secretion,390 its role in DCs is not wel understood. This knowledge gap regarding the role of 
SIRT1 in  DC function, and subsequent antiviral immune responses,  prompted the studies 
discused in this disertation. Given the central role SIRT1 plays in numerous pathways, and 
therefore various  disease proceses, much efort  has been  directed at developing SIRT1 
activators and inhibitors. 
 
Figure 1.3: Sirtuin 1 – complex roles,  many targets. SIRT1 interacts  with a  plethora  of 
pathways and health-relevant proceses including: genomic stability, stres responses, celular development, 
metabolism, circadian rhythm, cardiovascular  disease, cancer, neurodegeneration, anxiety control, 
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Pro-survival role of SIRT1 during stress responses 
During celular  disturbances—including starvation,  hypoxia,  ER stres, genomic 
stres, oxidation, and inflammation—SIRT1 expresion and activity are  upregulated to 
facilitate the activation  of  necesary  pro-survival  pathways.  The breadth of  SIRT1 targets 
contributes to the complexity of the protein’s role during diferent stres conditions, as in the 
case  of autophagy induction. SIRT1 interaction  with components  of the autophagosomal 
machinery  has  been shown  by co-immunoprecipitation  of  SIRT1  with  ATG proteins.373 
Interestingly, global Sirt1-/- mice resemble Atg5-/- (autophagy  defective)  mice in  phenotype, 
including the accumulation  of  damaged  organeles in the cytoplasm,  disruption  of energy 
homeostasis, and early  perinatal  mortality.373 Aside from direct  deacetylation, SIRT1 can 
indirectly activate autophagy. For example,  SIRT1 negatively regulates mTOR,  which 
represes autophagy  during  nutrient-rich conditions, through the  TSC1/2 complex.394 
Studies  have also shown that  SIRT1  mediates mTOR represion and autophagy formation 
during  oxidative stres in embryonic stem cels.382 In addition, nutrient surveilance  by 
SIRT1 is  dependent on various FOXO transcription factors, which sense insulin signaling 
and regulate longevity in lower organisms.377, 379 For example, SIRT1 deacetylation of FOXO 
mediates starvation-induced autophagy in cardiomyocytes.390 Lastly, SIRT1  promotes 
autophagy in response to toxins, such as in the case of fluoride-induced  ER stres in 
ameloblasts.383 
Under  hypoxic conditions,  SIRT1 induces  hypoxia-inducible factor  2α (HIF2α) 
activity  by  direct  deacetylation to  promote cel survival.395 However,  SIRT1 inhibits the 
related factor HIF1α by deacetylating at K674, blocking its asociation with p300, and thus 
limiting cel proliferation during hypoxia.396 Furthermore, SIRT1 diferentialy regulates the 
transcriptional activities  of  HIF1α and HIF2α in a cancer cel-type  dependent  manner.397 
Together, these physiological responses ilustrate how changing levels of NAD+ and related 
metabolites during hypoxia can regulate celular responses through SIRT1 to preserve energy 
homeostasis. 
In an efort to  preserve cel function, SIRT1 can also coordinate  multiple stres 
response pathways simultaneously. Folowing a heat or protein aggregation chalenge, SIRT1 
promotes transcription of heat shock response (HSR) genes via direct deacetylation of heat 
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shock factor  protein  1 (Hsf1).398 Yeast studies  have shown that the  HSR and the  UPR 
participate in a stres response network,399, 400 and subsequent work has shown that activation 
of the HSR by the UPR is facilitated by Sir2 (yeast homolog of SIRT1).401 Specificaly, Sir2 
was esential for HSR- and UPR-induced Hsf1 activation, and exces Sir2 compensated for 
UPR-dependent Hsf1 activation in UPR-defective yeast strains.401 Likewise, while Sir2 was 
upregulated  by the  UPR, it also served as  negative feedback to  prevent the  deadly 
consequences of chronic UPR.401 Congruently, SIRT1 has been asociated with the UPR in 
mammalian  models,  whereby it  deacetylates  XBP1s387 to curb  UPR-induced cel apoptosis 
and ER-stres mediated liver dysfunction.388, 389 
While  much research since  SIRT1’s  discovery  has  been focused  on its non-histone 
targets, the significance of  SIRT1 in  mediating genomic stability is wel evidenced during 
hematopoietic stem and progenitor cel (HSPC) maintenance. Using bone marow specific 
Sirt1-ablated  mice, researchers  observed aberant  HSPC expansion  under 5-Fluorouracil-
induced  hematopoietic stres,  which  was asociated  with genomic instability, the 
accumulation of DNA damage, and the eventual los of long-term progenitor populations. 
Likewise, SIRT1 was shown to bind the Hox9 gene and deacetylate H4K16, thus promoting 
polycomb-specific represive  histone  modifications. Together, these findings  demonstrate 
two interconnected roles for SIRT1 in HSPC homeostasis, both via epigenetic regulation of 
a key developmental gene and by promoting genomic stability in adult stem cels.402 
Additionaly,  SIRT1  poseses antioxidant and anti-inflammatory functions. For 
example, SIRT1-targeted DNA repair factor KU70 promotes survival by preventing BCL-2 
asociated  X  protein (BAX) from entering the  mitochondria to activate oxidative stres-
induced apoptosis.403 SIRT1  deacetylation  of  FOXO1,  FOXO3, and  FOXO4 induces cel 
cycle arest and resistance, while inhibiting apoptosis, during oxidative stres.404-406 In starved 
mouse astrocytes,  SIRT1  upregulation increased the expresion  of antioxidant enzymes 
(superoxide  dismutase, catalase) in a  FOXO4-dependent  manner and suppresed the 
expresion of pro-inflammatory cytokines.407 Interestingly, while SIRT1 activity rises during 
acute inflammation, the  protein plays  dual regulatory roles. The  deacetylation of the 
RelA/p65 subunit  of  NFκB408 by  SIRT1 leads to the transcriptional represion  of NFκB-
activated inflammatory cytokine expresion,409 while  SIRT1 concurently stimulates anti-
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inflammatory gene expresion  by targeting  RelB.409 In contrast,  SIRT1 activity diminishes 
during prolonged inflammation, which may explain the steady hyperactivation of NFκB in 
chronic inflammatory diseases such as obesity, atherosclerosis, diabetes, and COPD.410  
Pleiotropic effects of SIRT1 on age-related diseases 
 As  of now, there are few identified SIRT1 polymorphisms asociated  with  human 
disease, al of which are related to metabolism. Three SIRT1 SNPs has been asociated with 
diferences in whole-body energy expenditure in  Finnish subjects.411 Recently, a study 
reported a link between SIRT1 gene  polymorphisms and  obesity in children.385 Finaly, 
multiple family  members afected  by type  2  diabetes were found to cary a SIRT1-L107P 
point  mutation,  which contributed to insulin resistance and the overproduction  of 
inflammatory  mediators  by pancreatic β-cels implicated in the  pathogenesis  of type  1 
diabetes.384 Nonetheles, given its central role in a plethora of celular proceses, SIRT1 has 
an intricate, two-sided asociation with cardiovascular health, cancer, and neurodegeneration, 
in addition to metabolic disease. 
The maintenance  of relatively constant  blood glucose concentration is esential to 
provide fuel to tisues,  which is regulated through various  proceses, including intestinal 
glucose uptake, hepatic glucose output and uptake, and utilization and storage in peripheral 
tisues.376 Intriguingly,  SIRT1 can suppres  hepatic glucose production  by  deacetylating 
CREB-regulated transcription co-activator 2 (CRTC2), but can also stimulate gluconeogenic 
transcriptional  programs via activation  of  FOXO1 and  PGC1α.412-414 Despite this duality, 
SIRT1  may serve as an insulin sensitizer, as SIRT1 activation  protects mice from diet-
induced and genetic insulin resistance.415, 416 Moreover, SIRT1 can inhibit glycolysis via 
activation  of PGC1α,414 and increase mitochondrial oxidative  metabolism via inhibition  of 
HIF1α.417 Lastly, SIRT1 promotes insulin secretion from pancreatic β-cels by transcriptional 
represion of mitochondrial uncoupling protein 2 (UCP2).418 
 Lipid  homeostasis is likewise influenced  by  SIRT1 activity. The  key transcription 
factor controling genes involved in lipid synthesis, liver  X receptor (LXR), is activated via 
SIRT1 deacetylation,419 contributing to cholesterol metabolism. SIRT1 inhibits adipogenesis 
and enhances fat  mobilization through lipolysis  by suppresing the activity  of  PPARγ.420 
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Aside from inhibiting glycolysis, SIRT1-mediated  PGC1α activation transcriptionaly 
stimulates faty acid  uptake and/or β-oxidation.421 In support  of this,  SIRT1 activation 
protects  mice from  diet-induced  obesity  by increasing faty acid  oxidation,422 while Sirt1-/- 
mice are susceptible to hepatic steatosis under standard and high-fat diets.421, 423 
 Strong evidence exists in favor  of  SIRT1’s cardioprotective  properties. 
Overexpresion of Sirt1 is beneficial in both cardiac myocytes and in vascular cels,424-428 and 
studies suggest that  many  of the  positive efects  of  Resveratrol (details forthcoming in 
chemical  modulator section), such as  upregulation  of antioxidant enzymes, are  SIRT1-
dependent.429 Likewise, SIRT1 overexpresion in cultured endothelial cels  decreased the 
expresion and activity  of tisue factor (initiator of coagulation), via NFκB-inhibition.430 
Another SIRT1 activator, SRT1720, significantly reduced the number of ischemic foci and 
atenuated inflammatory gene activation in the  hearts  of  mice fed a  high-fat  diet.431 
However, while a study reported that  2.5- to 7.5-fold Sirt1 overexpresion reduced age-
dependent cardiac dysfunction in mice, 12.5-fold overexpresion increased cardiomyopathy 
and oxidative stres.424 
SIRT1 has a fascinating yin-yang relationship with diferent types of cancers, serving 
as  both an oncogene and tumor suppresor. On  one  hand, SIRT1 can  be seen as a tumor 
promoter as it deacetylates p53, a tumor suppresor, leading to the inhibition of apoptosis in 
injured cels.432 SIRT1 is significantly elevated in human prostate cancer, leukemia, primary 
colon cancer, and al non-melanoma skin cancers, among others.433-435 Thus, higher SIRT1 
levels  may hamper p53-dependent cel cycle arest and apoptosis in response to  DNA 
damage and  oxidative stres, two contributing factors to  oncogenic  mutations. SIRT1’s 
oncogenic efect may also be atributed to los of function in SIRT1’s inhibitor, DBC1, as 
deletions in  DBC1 in  breast cel lines increase the risk for tumorigenesis.436 Lastly, los of 
global  H4K16 acetylation combined  with H4K20 tri-methylation is a  halmark  of  human 
cancers.437 SIRT1 deacetylates H4K16 and H3K9 at promoters of several tumor suppresor 
genes, thereby recruiting methyltransferases and promoting gene silencing.438, 439 
On the  other  hand,  SIRT1 is  often  decreased in chronic inflammation,  which is a 
risk factor for certain cancers. Downregulated SIRT1 expresion has been reported in human 
glioblastoma,  bladder carcinoma,  prostate carcinoma,  ovarian cancer, and  hepatic 
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carcinoma.438 SIRT1 antitumor activity is supported  by the fact that SIRT1 deficiency 
hampers DNA repair,  which can lead to severe genetic instability.  Likewise, as  mentioned, 
SIRT1 promotes mitochondrial faty acid  oxidation,  which upsets tumor cels’ reliance  on 
glycolysis, known as the Warburg efect. Mutations in the tumor suppresor BRCA1 reduce 
SIRT1 expresion, thus increasing the risk for breast, ovarian, falopian, and prostrate cancer 
in humans.440 Survivin, an oncogene expresed in most cancer cel types, is represed at the 
promoter by  SIRT1-mediated  deacetylation  of  H3K9. SIRT1 also blocks nuclear 
translocation of the oncogenic protein β-catenin, such that Sirt1 overexpresion in a mouse 
model  of colon cancer significantly reduced tumor formation and  morbidity.441 Thus, the 
contribution of SIRT1 to cancer development is dependent on other celular parameters, at 
both the genomic and epigenetic levels.  
Finaly,  SIRT1  has shown  beneficial roles in  multiple  models  of neuropathology, 
primarily by deacetylating protein targets that protect against neurodegeneration.442 Patients 
with  Alzheimer’s  disease  have lower SIRT1 gene expresion, which corelates  with the 
accumulation  of neurofibrilary tau tangles.443 Evidence from in vitro and animal models 
indicates that increased SIRT1 activity, by genetic  or chemical means, may  be  protective 
against  Parkinson’s  disease  by reducing α-synuclein-mediated toxicity.444, 445 Three  diferent 
mouse  models  have shown that  SIRT1 can also  protect against  Huntington’s  disease  by 
activating PGC1α to prevent huntingtin-induced mitochondrial dysfunction and to reduce 
protein aggregation.446 Even in a  mouse model  of  MS, experimental autoimmune 
encephalitis (EAE),  SIRT1 activation  may prevent  neuronal  damage and long-term 
dysfunction.447 Despite the duality of SIRT1 activity in human pathologies, its beneficial role 
in preventing autoimmune demyelination and neurodegeneration is quite robust. 
SIRT1 regulates immune cel differentiation and activation 
The significance  of  SIRT1, especialy  with regards to immune function, is 
highlighted by studies in Sirt1-nul mice. These Sirt1 mutants are smaler and harbor notable 
developmental defects of the retina and heart, with most dying postnataly.448 Younger Sirt1-/- 
mice are prone to eyelid inflammation, while mice 2 years of age present with increased anti-
nuclear antigen antibodies in the sera, deposits of IgM and IgG immune complexes in the 
 40 
liver and kidney, and exhibit a SLE-like phenotype.449, 450 SIRT1-based therapies and various 
KO mouse models have helped delineate the role of SIRT1 in innate and adaptive immune 
responses, including those during infection and pulmonary disease. However, while studies 
have begun to elucidate the roles of SIRT1 in macrophages and T cels, much les is known 
about this protein’s role in DCs.  
The majority  of  SIRT1 functions  observed in the immune system arise from the 
regulation of NFκB and AP-1 pathways. The NFκB pathway is a central signaling node in 
inflammatory cytokine stimulation and lymphocyte activation. As previously stated, SIRT1 
deacetylation of the p65 subunit at K310 leads to reduced NFκB transcriptional activity.408 
Not surprisingly, p65 transcription  positively feedbacks  onto  SIRT1, resulting in increased 
mRNA levels.451 Activator  protein  1 (AP-1, dimeric complex  of JUN and  FOS) 
transcriptional activity has an esential role in immune response activation, particularly in T 
cels, and is also targeted by SIRT1 deacetylation.450 
Macrophages, the most abundant innate immune cel type, are a main source of pro-
inflammatory cytokines  TNFα, IL-6, and IL-1 in response to infection and inflammation. 
SIRT1’s inhibitory role  on NFκB signaling  has an esential role in suppresing the  pro-
inflammatory  phenotype  of  macrophages.406, 452 For example, the ablation  of Sirt1 in 
macrophages, using a myeloid cel-specific Sirt1 KO mouse, rendered NFκB hyperacetylated 
and resulted in increased transcriptional activation  of  proinflammatory target genes.409 
Interestingly, XBP1s is critical for IFNβ production in  macrophages.453 Given that SIRT1 
inhibits XBP1s,387 the suppresion  of the  UPR in  macrophages  may serve to inhibit the 
activation of at least part of innate immune response. 
Far les  has  been reported about the role  of  SIRT1  within DCs,  which  herald the 
presence  of a foreign invader and initiate the adaptive immune response via cytokine 
production and antigen-presentation to  T cels. However, the data suggests that SIRT1 
programs DCs to promote inflammatory immune responses.454, 455 One study examined DC-
specific Sirt1 KO  mice and  observed no changes in  DC  maturation,  diferentiation,  or 
development compared to  WT  DCs;  however, these Sirt1-/- DCs  produced  higher levels 
inflammatory cytokines  upon TLR stimulation.454 Moreover, these  DC-specific Sirt1 KO 
mice were resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, exhibiting 
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a significant reduction in central nervous system (CNS)  pathology,  much fewer Th17 and 
Th1 celular infiltrates, and a significant increase in Treg cel populations.454 A second study 
demonstrated that the lack  of  SIRT1 in  DCs reduced  macrophage and eosinophil lung 
infiltration in a  murine  model  of OVA-induced airway  disease.455 The  data suggest that 
SIRT1 represed PPARγ activity within DCs, thereby promoting their maturation and pro-
Th2 skewing activity. Accordingly, mice treated with pharmacological SIRT1 inhibitors had 
reduced Th2 responses and were protected against alergic airway inflammation.455  
The role of SIRT1 in the adaptive immune response has been primarily focused on 
the activation and diferentiation of T cels. SIRT1 protein levels are dramaticaly elevated in 
anergic T cels, compared to activated T cels or mature, naïve T cels.450 Sirt1-nul mice do 
not  harbor aberant  T  or  B cel  numbers as compared to  WT litermates, indicating that 
SIRT1 may not be critical for these cels’ development.390 However, T cels from Sirt1-nul 
mice are  hyperproliferative and activated  without  CD28 co-stimulation; TCR stimulation 
alone leads to as much proliferation in Sirt1-/- T cels as TCR/CD28 co-stimulation.450, 456 In 
addition, T cels isolated from OVA-sensitized Sirt1-nul mice proliferate more upon OVA 
re-exposure and  produce  more IL-2, IFNγ, and IL-5.450 This T cel  hyperactivation results 
from the los of suppresion of NFκB and AP-1 transcriptional activity,450 as wel as a lack of 
SIRT1-dependent inhibition  of BCLAF1, a  BCL-2  binding  protein required for  T cel 
activation.456 IL-2 provides a crucial signal for maintaining the viability and proliferation of 
activated CD25+ T cels  by suppresing FOXO1,  3, and  4 to  prevent apoptosis.457 
Additionaly, data reveals that IL-2 can suppres Sirt1 transcription by sequestering FOXO3a 
to the cytoplasm, thereby reversing T cel tolerance,  which is characteristic  of  T cel 
anergy.458 This may explain the aforementioned hyperproliferation and activation of Sirt1-/- T 
cels, and the greater mRNA and protein expresion of SIRT1 in anergic T cels.450, 456 
SIRT1 is implicated in the diferentiation of activated T cels, although the specific 
mechanisms are not as clear. One group reported how ATF-like (BATF) directly suppreses 
the transcription of Sirt1, and demonstrated that Batf-/- CD8+ cels had lower acetylation at 
the  TBET  promoter and lower Ifng, Ifngr1, and Il12rb2 expresion.459 Conversely, Sirt1-/- 
CD4+ T cels produced more IL-5 and IFNγ protein upon in vitro stimulation. SIRT1 may 
inhibit the diferentiation of CD4+ T cels into inflammatory Th17 cels and the expansion 
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of  Tregs by suppresing  STAT3 activity.460, 461 Moreover, SIRT1 is a  negative regulator  of 
Treg function via FOXP3  deacetylation, whereby hyperacetylation stabilizes the FOXP3 
protein and enhances Treg suppresive activity.462, 463 In agreement, Sirt1f/f-Foxp3-Cre+ mice 
exhibited  prolonged survival  of  MHC-mismatched cardiac alografts,  while efector  T cel 
responses were unafected.462 Likewise, administration  of a  SIRT1 activator in a  mouse 
model of autoimmune uveoretinitis suppresed numbers of retinal infiltrating T helper cels, 
with a greater reduction in  Tregs as compared to  Th1,  Th2 and  Th17 cels.464 Overal, 
SIRT1’s regulation of NFκB, AP-1, and STAT3 points to SIRT1 being a suppresor of pro-
inflammatory T cel responses. 
SIRT1 and anti-microbial immune responses 
Similar to autophagy,  SIRT1 is caled  upon  during celular stres to reestablish 
celular homeostasis. As al sirtuins require NAD+ for activity, their function is tightly linked 
to the metabolic status of the cel. Therefore, a stres such as bacterial or viral infection wil 
upset the cel’s energy balance, leading to the activation of sirtuin transcription and activity. 
Given that  many of  SIRT1’s functions, including glycolysis inhibition and faty acid 
oxidation, are contrary to  what an actively replicating virus desires, SIRT1  may  be an 
evolutionary antiviral defense. In fact, the E. coli sirtuin homologue,  CobB, has  been 
reported as a host defense mechanism against bacteriophages, whereby knockdown of CobB 
promoted phage  plaque size and  overexpresion  of CobB reduced  phage titers.465 
Furthermore, al seven  human sirtuins have recently been shown to  have  broad-range 
antiviral properties against both DNA and RNA viruses.465 
In particular, the importance of SIRT1 during antiviral defense is underlined by the 
ways in  which various viruses  highjack the  deacetylase. While SIRT1  has  been shown to 
restrict viral replication of HCMV, HSV, adenovirus type 5 (Ad5), and H1N1,465 HIV and 
hepatitis  B virus (HBV) leverage  SIRT1 activity to their advantage. The  HIV  Tat  protein 
facilitates elongation of mRNA transcription, and once the transcripts are completed, Tat is 
recycled via  SIRT1  deacetylation to alow for continued HIV genomic replication.466 
Conversely, Tat binds the catalytic domain of SIRT1, blocking its ability to deacetylate and 
inhibit NFκB. Interestingly, HIV has two NFκB binding sites, such that with Tat-induced 
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SIRT1 suppresion, transcriptional activity of both NFκB-responsive genes and HIV-specific 
genes are enhanced.467 During  HBV infection of  human cel lines, SIRT1 physicaly 
asociates with the viral DNA template; as SIRT1 is upregulated in expresion and activity, 
so is viral replication.468 The HBV X protein blocks SIRT1 so it cannot repres the activity of 
β-catenin, known to promote the development of HBV-induced hepatocelular carcinoma.469 
In contrast to SIRT1’s involvement in viral infection, les is known about the role of 
SIRT1 in host  defense against  bacteria. One study,  utilizing SIRT1 activators,  SIRT1 
inhibitors, and a myeloid-specific Sirt1 KO mouse (Sirt1f/f-LysM-Cre), reported that SIRT1 
has litle influence  on  macrophage and  neutrophil antimicrobial functions.470 Likewise, 
myeloid Sirt1 expresion did  not alter  mortality in gram-negative toxin-induced shock  or 
gram-positive  bacteremia.470 Thus,  while  SIRT1 serves to repres  macrophage-induced 
inflammation,409 it  does  not alter the intrinsic anti-bacterial characteristics of this innate 
immune cel.  
Modulation of SIRT1 activity: natural and synthetic compounds 
 The activity and expresion  of  SIRT1 are tightly regulated at  many levels—from 
general mechanisms, such as substrate availability, tisue and subcelular localization, to gene-
specific regulatory  mechanisms, such as activation  of transcription factors, regulation  by 
microRNA, post-translational  modification, and  protein-protein interaction. SIRT1’s 
activity is closely controled  by the availability of  NAD+, a required co-factor, and 
nicotinamide (NAM), a  by-product  of catalysis that serves as an endogenous inhibitor.471 
Another axis of regulation is the positive feedback between SIRT1 and AMP-activated kinase 
(AMPK),  which upon sensing a rise in the intracelular AMP/ATP ratio facilitates gene 
transcription to increase  ATP generation.472, 473 AMPK activation also increases the 
intracelular  NAD+/NADH ratio, leading to sirtuin activation.474 Moreover,  SIRT1 
deacetylates  LKB1, an activator  of  AMPK, thus further  promoting its  own activity.475 In 
terms  of  SIRT1 expresion,  multiple transcription factors regulate  SIRT1  mRNA levels, 
including p53, FOXO3a, E2F1, and c-Myc, in response to stimuli such as growth factors, 
cel cycle conditions, and apoptotic signals.380, 476, 477 As  previously  noted, many of these 
transcription factors are also deacetylated by SIRT1, providing a feedback mechanism in the 
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regulation of SIRT1 expresion. In addition, SIRT1 expresion can be post-transcriptionaly 
regulated  by  microRNA;  miR-34a and  miR-199 have  been reported to suppres  SIRT1 in 
prostate cancer lines and cardiomyocytes, respectively.478, 479 Postranslational modifications, 
such as  phosphorylation  by c-Jun  N-terminal  kinases  1 and  2 (JNK  1,  2), alter  SIRT1 
localization, activity, and stability.480, 481 Finaly, protein regulators influence SIRT1 activity 
via physical interaction, such as the active regulator of SIRT1 (AROS)482 and the neuronal 
protein necidin,483 which serve as enhancers, or DBC1, which inhibits SIRT1 by binding to 
the core catalytic domain.436 
Given the prospective therapeutic benefits of promoting or blocking SIRT1 activity 
under diferent conditions, researchers  have  been enthusiasticaly studying SIRT1 
modulators. Resveratrol (SIRT1 EC1.5 = 46.2 µM),416 a polyphenol naturaly occuring in the 
grape Vitis vinifera,484 was initialy identified as a sirtuin activator and subsequently shown to 
expand lifespan in yeast.485 Although Resveratrol can promote the activity of SIRT1, it is stil 
inconclusive and hotly debated whether the efects are direct or indirect, such as via AMPK-
dependent  mechanisms.486 Resveratrol also targets numerous other enzymes and acts as a 
powerful antioxidant  on its  own,  making its efects dificult to interpret.487 Structuraly 
unrelated imidazothiazole-containing SIRT1 activators  with increased potency  have  been 
synthesized by Sirtris Pharmaceuticals, including SRT1460, SRT1720, SRT2104, SRT2183, 
and  SRT2530; however, like  Resveratrol, there remains much dispute  over their  biological 
actions.488, 489 
Regardles  of these controversies over mechanism, SIRT1 activators  have been 
confirmed to have numerous health benefits in various species.377 For example, Resveratrol, 
SRT1460, SRT1720, and SRT2183 have been reported to improve insulin sensitivity, lower 
blood glucose, and increase  mitochondrial capacity in  diet-induced and geneticaly  obese 
mice.416 Likewise, SRT1720, the most potent and specific of the Sirtris compounds (SIRT1 
EC1.5 =  0.16 µM,  SIRT2 EC1.5 =  37 µM,  SIRT3 EC1.5 >  300 µM),416 was shown to extend 
lifespan  of adult  mice  on a  high-fat  diet, in addition to  decreasing obesity  health risks.431 
Recently, pulmonary studies utilizing SRT1720 have shown how SIRT1 activation protects 
against emphysema in a mouse model of COPD 490 and alergen-induced inflammation in a 
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mouse  model  of asthma.491 Importantly, SRT2104 and  SRT2379 are curently in human 
clinical trials to study their efects during sepsis and diabetes (htps:/clinicaltrials.gov). 
Unlike the controversy-laden field  of  SIRT1 activators, there is  more clarity  with 
regards to  SIRT1 inhibitors. Among them,  Sirtinol  was the first compound reported to 
inhibit the activity of sirtuins (SIRT1 IC50 =131 µM,  SIRT2 IC50 =46 µM).492, 493 Newer, 
Sirtinol-related inhibitors with far greater potency, such as Salermide (SIRT1 IC50 = 43 µM), 
have  been  developed.494 NAM and  NAM-related analogues serve as adequate inhibitors in 
vitro by occupying the NAM subpocket of the NAD+ binding site. Yet, with an IC50 of ~85 
µM towards SIRT1, and a concentration of <1 µM in mammalian serum, NAM is les likely 
to impair SIRT1 in vivo.495-497 Additional subclases of SIRT1 inhibitors include Cambinol 
(SIRT1 IC50 = 56 µM,  SIRT2 IC50 =  59 µM),498 Tenovin-6 (SIRT1 IC50 =  20 µM),499 and 
Suramin (SIRT1 IC50 = 0.3 µM, SIRT2 IC50 = 1.2 µM).499 However, the indole-based EX-
527 is  one  of the  most  potent and selective SIRT1 inhibitors today (IC50 = 38nM),  with 
negligible  potency against  SIRT2 (IC50 =19.6  µM)  or  SIRT3 (IC50 = 48.7  µM), and no 
activity against clas I/II  HDACs.500 EX-527 preferentialy binds  SIRT1  while it is in 
complex  with the yet-to-be-released  2’-O-acetyl-ADP-ribose, locking the  deacetylase in a 
“closed” state.375 
Originaly, the impetus for  developing  potent sirtuin inhibitors stemmed from a 
desire to modulate cel survival and proliferation. Several studies have reported the benefits of 
SIRT1 pharmacological inhibition in the seting of cancer.501, 502 In fact, Cambinol was first 
developed as a potential antitumor drug498 and later discovered to display anti-inflammatory 
properties in vivo.503 Although contrasting to  SIRT1’s reported anti-inflammatory roles, 
SIRT1 inhibitors have been succesfuly used in animal models to treat certain inflammatory 
disorders.503-506 For example, administration  of Sirtinol  or  Cambinol has been shown to 
reduce alergic airway inflammation and Th2 cytokine responses.455, 507 
Summary of rationale and thesis aims 
The  ubiquitous  human  pathogen  RSV predominantly causes  mild respiratory tract 
infection. Nonetheles, RSV infection remains the leading global cause of LRTI in children, 
and a source of significant morbidity and mortality among the vulnerable including infants, 
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the elderly, and those with chronic respiratory  diseases. Infants  hospitalized  with a severe 
RSV infection are at a greater risk for  developing alergic asthma and recurent  wheezing 
later in life, suggesting that a chronic alteration  of the  pulmonary immune environment 
ensues even after succesful viral clearance. 
Activated pulmonary DCs drive innate and adaptive immune responses to viral 
pathogens through the production of proinflammatory cytokines and the activation of T cel 
responses in  LDLNs. Detection  of viral antigens  by  DCs requires signaling through 
endosomal TLRs. As RSV enters the host cel cytosol directly through membrane fusion, an 
alternate antigen delivery is necesary to reach these endosomal compartments. Our lab and 
others  have shown that  DCs rely  on autophagy to  mediate  TLR-dependent activation, 
cytokine production, and efective APC function.  
Autophagy is a conserved intracelular  membrane traficking  pathway  whereby 
cytoplasmic material is sequestered within double-waled vesicles and degraded upon fusion 
with lysosomes.  This  proces  maintains celular  metabolic equilibrium and  promotes cel 
survival  during  physiological and  pathological stres conditions. Within  APCs, autophagy 
facilitates TLR signaling and MHC  molecule  peptide loading through  delivery  of viral 
antigens to acidified endosomes. 
Interestingly, key proteins that orchestrate autophagosome formation are targeted by 
SIRT1, a NAD+-dependent histone and  protein deacetylase. SIRT1 impacts  many areas of 
biology and  pathophysiology, and several Sirt1 variants have  been linked to  human 
metabolic  disorders. Importantly,  SIRT1 diversely regulates immune function, such as 
lymphocyte activation, proliferation, and diferentiation, and macrophage cytokine secretion. 
However, the role of SIRT1 in DC biology and its subsequent impact on adaptive immunity 
has not been elucidated. 
The major aims of this disertation were to determine (a) whether SIRT1 regulated 
DC activation and autophagy-mediated proceses during RSV infection (Chapter 3) and (b) 
whether the absence of SIRT1 activity altered the antiviral immune response (Chapter 4). To 
addres these questions, SIRT1 within DCs was chemicaly and geneticaly targeted and the 
efects were examined in a mouse model of RSV infection. Results demonstrate that RSV-
infected  DCs lacking functional  SIRT1 failed to appropriately  upregulate autophagy and 
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cytokine  production,  while retaining the capacity to stimulate T cels and  present antigen. 
Likewise, DC-specific Sirt1 knockout  mice (Sirt1f/f-CD11c-Cre+) exhibited exacerbated, 
prolonged RSV-induced lung pathology, highlighting the esential role of SIRT1-mediated 
DC cytokine production in fine-tuning the antiviral adaptive immune response. Altogether, 
these findings expand  our  understanding  of the innate immune response  during  RSV 
infection and identify SIRT1 as a  potential therapeutic target for the treatment and 
prevention of severe viral-induced lung pathology. 
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CHAPTER 2: 
Materials & Methods 
 
Chemicals and reagents 
 Bafilomycin (Santa Cruz Biotechnology, Dalas, TX), EX-527 (SIRT1 Inhibitor III, 
Calbiochem,  Darmstadt,  Germany), SRT1720 (Calbiochem), and Tunicamycin (Sigma-
Aldrich, St. Louis, MO) were reconstituted in DMSO and diluted in culture medium for in 
vitro work. Based on previous reports,375, 500 we chose a 1 µM EX-527 dose in vitro, with no 
significant changes in  DC cytokine  production at greater concentrations.  We  observed 
comparable viability in control and EX-527-treated cels  by flow cytometry (Live/Dead 
Fixable Yelow, Life Technologies, Carlsbad, CA) and exclusion dye stain (Trypan Blue). For 
in vivo experiments, mice received daily intraperitoneal (i.p.) injections of 100 µL (1 mg/kg) 
EX-527 reconstituted in  DMSO and  diluted in  normal saline; controls received  DMSO-
saline. Dose response asays revealed that administrating 10 mg/kg EX-527 to RSV-infected 
mice caused a rebound in Sirt1 and a reversal of the phenotype observed at the 1 mg/kg EX-
527  dose.  3-methyladenine (3-MA,  Sigma-Aldrich) and recombinant  mouse  TNFα (R&D 
Systems, Minneapolis, MN) were reconstituted in PBS + 0.1% BSA and used at 10 µM or 
10 ng/mL, respectively. Imiquimod (R837, InvivoGen, San Diego, CA) was reconstituted in 
endotoxin-free water and used at 1 µg/mL. Ovalbumin (Sigma-Aldrich) was reconstituted in 
PBS to a stock concentration  of  2  mg/mL. RPMI  1640 (Lonza,  Walkersvile,  MD) and 
HAM-F12 (Life  Technologies)  media  were  used for cel culturing.  To induce amino acid 
starvation, the cel culture medium was exchanged with HBSS (Life Technologies). 
 
Cel lines 
 MLE-12 and LA4 cels were purchased from ATCC (Manasas, VA). MLE-12 cels 
were  maintained in  HITES  medium, a supplemented  RPMI  1640-based  medium (1X 
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insulin transferin selenium-X,  100  µg/ml streptomycin,  100  U/ml  penicilin,  10  nM β-
estradiol, 10 nM hydrocortisone, 2% FBS). LA4 cels were cultured in HAM-F12 medium 
supplemented with 1% Pen/Strep + 10% FCS. 
 
Mice 
C57BL/6J (BL6), B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), B6;129-Sirt1tm1Ygu/J 
(Sirt1f/f), and  C57BL/6J-Tg(Itgax-cre,-EGFP)4097Ach/J (CD11c-Cre-GFP)  mice  were 
purchased at 6–7 weeks of age from The Jackson Laboratory (Bar Harbor, ME). Sirt1f/f mice, 
in which two loxP sites flank Sirt1 exon 4, were crosed to CD11c-Cre-GFP transgene mice. 
As the Sirt1f/f mice were on a mixed C57BL/6J;129 background, we backcrosed the Sirt1f/f-
CD11c-Cre progeny to a  C57BL/6J  background for  6 generations. The resultant Sirt1f/f-
CD11c-Cre+ mice harbor CD11chigh cels producing a truncated, catalyticaly inactive 
SIRT1,  mimicking a Sirt1-nul genotype.448 Al breeding took  place in-house at the 
University  of  Michigan (Ann  Arbor,  MI). Animal  work  protocols were reviewed and 
approved by the University of Michigan University Commitee on Care and Use of Animals. 
Deletion of exon  4 was verified  by  DNA analysis. Day  10  BMDCs were cultured 
from Sirt1f/f-CD11c-Cre mice, and their DNA was extracted,  purified,  PCR amplified, and 
separated by 2% agarose gel. Excision was asesed by the presence of an excision band using 
primers flanking the Sirt1 exon  4 excision site, according to the Jackson  Labs genotyping 
protocol (Forward  =  5'-AGGCGGATTTCTGAGTTCGA,  Reverse  =  5’-
CGTCCCTTGTAATGTTTCCC). The absence  of Sirt1 exon  4 was verified  using 
homemade SYBR primers flanking the interior  of the exon (Forward:  5’-
TGAGCTGGGTGTGGTGGCG, Reverse: 5’-ATTCAATAGCCACATGCAGTCACA).  
1 cycle 94°C 3 min 
25 cycles 
94°C 30 sec 
56°C 30 sec 
72°C 30 sec 
1 cycle 72°C 2 min 
1 cycle 4°C Indefinite 
Table 2.1: PCR settings for homemade Sirt1 exon 4 primers. 
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Respiratory syncytial virus 
 The  RSV strain  2-20,  kindly  provided  by  Dr.  Martin  Moore (Emory  University, 
Atlanta, GA), was originaly isolated from a severely il RSV-infected infant.95 Line 19 RSV 
(antigenic subgroup A), originaly obtained from a sick infant at the University of Michigan 
Hospital System, was shown in animal models to mimic human infection by eliciting airway 
mucus production upon inoculation with 1 x 105 PFU (plaque forming units) RSV.93 RSV 
strains  were  propagated in  our laboratory in  HEp-2 cels (ATCC).  Mice  were infected 
intratrachealy (i.t.) via tongue-pul with 1.5 x 105 RSV.  
 
Lung histology 
Serial 6 µm sections were obtained from parafin-embedded, 10% formalin-fixed left 
lungs stained with hematoxylin and eosin (H&E). Intracytoplasmic and luminal mucin was 
asesed by periodic acid-Schif (PAS) stain. 5 sections were analyzed per mouse lung, with 2 
lung slices/section/mouse to select representative slides. PAS-stained slides  were  blindly 
scored for goblet cel  hyperplasia  by light  microscopy.  The folowing scoring system  was 
used: 1, absent; 2, staining in multiple airways; 3, staining in multiple airways with mucus 
plugging; 4, severe mucus plugging in multiple airways. 
 
BMDC culture 
Bone  marow–derived  DCs (BMDCs)  were isolated from  whole  bone  marow  of 
naïve  C57BL/6  mice, Sirt1f/f-CD11c-Cre+ mice,  or litermate controls.  Bone  marow cels 
were seeded into tisue culture flasks containing RPMI 1640–based complete medium (10% 
FCS, 1% penicilin/streptomycin, 1% glutamate (Life Technologies), 1% Na Pyruvate (Life 
Technologies),  1%  non-esential amino acids (Life  Technologies),  50 µM β-
mercaptoethanol) supplemented  with  15  ng murine GM-CSF/mL (R&D  Systems, 
Minneapolis,  MN) at 10%  CO2,  37ºC. C57BL/6  mouse-derived cels  were fed  on  days  3 
and  5 and  harvested  on  day  7, a time  point  by  which cels  were ≥85%  CD11b+ CD11c+ 
BMDCs by flow cytometric analysis. Cels derived from the Sirt1f/f-CD11c-Cre± mice were 




 Alveolar epithelial cels (AECs) were isolated from whole lungs of naïve mice. Lungs 
were  digested in  Dispase (BD  Biosciences), filtered through  25  µm  mesh, and  depleted  of 
immune cels through labeling  with  biotinylated antibodies to  CD16/32 and  CD45 (BD 
Pharmingen, San Diego, CA), folowed by labeling with anti-biotin microbeads and pasage 
through a  MACS column (Miltenyi  Biotec,  Auburn,  CA).  Depleted cel suspensions  were 
adherence-purified  overnight in  DMEM-based complete  media, and  non-adherent cels 
cultured for  4  days in complete  media  within fibronectin-coated  wels, yielding ≥90% e-
cadherin positive cels. Cultures were RSV-infected at 1:1 MOI. 
 
Lymph node re-stimulation and protein quantification 
 Lymph  nodes  were isolated  by  mechanical  disruption, cultured, and then 
restimulated with RSV for 48 h before colecting supernatants for protein analysis on a Bio-
Plex  Suspension  Aray  System (Bio-Rad,  Hercules,  CA), according to the  manufacturer’s 
protocol.  Custom  kits containing antibody-coated  beads for  mouse IL-4, IL-5, IL-13, IL-
17a, and IFNγ were used to asay cytokine concentration (Bio-Rad). Results are reported as 
fold diference over concentrations in control or unstimulated cels. 
 
Stimulation of whole cel populations from mouse spleen 
Total cel  populations (APCs,  T cel, etc.)  were isolated from  minced spleens from 
Sirt1f/f-CD11c-Cre±  mice. Once  minced, spleens  were forced through a 100  µm  nylon 
strainer. After red blood cel (RBC) lysis, single cel suspensions were plated at 2 x 106 in 24-
wel culture plates and stimulated with 2 µg/mL of anti-CD3 (eBioscience). After 72 h, cel 
supernatants were colected and analyzed by Bio-Plex, as described under “LN re-stimulation 
and protein quantification.” 
 
CD4+ T cel isolation and DC-T cel co-culture  
RSV-responsive CD4+ T cels were isolated from mediastinal LN of BL6 mice 8 dpi. 
Ovalbumin (OVA)-responsive T lymphocytes were isolated from minced spleens from OT-
II transgenic mice. LN or minced spleens were forced through a 100 µm nylon strainer and 
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underwent RBC lysis. Then, CD4+ T cels were isolated via magnetic bead selection: negative 
selection protocol for CD4+ T cels; positive selection for CD11c+ cels to eliminate residual 
APCs (Miltenyi Biotec). 5 x 105 T were plated per wel in 96-wel culture plates, on top of 5 
x 104 DCs treated 2 h previously with 1:1 MOI RSV, and where indicated pre-treated with 
10 µM EX-527 for 30 min prior to infection. In experiments conducted with OT-II T cels, 
DCs were treated  with  200  µg/mL whole  OVA for  4 h  prior to co-culture  with  OT-II  T 
cels. Co-cultures were colected after 24 h for mRNA analysis, or after 48 h for supernatant 




RNA was extracted as per Trizol reagent protocol (Life Technologies) or per Qiagen 
RNeasy  Mini  Kit  protocol (Hilden,  Germany), and  5-10 µg  were reverse transcribed into 
cDNA.  mRNA  was  determined  using  pre-developed Life  Technologies  primer/probe sets, 
TaqMan Universal PCR Master Mix (Life Technologies) or SYBR Green PCR Master Mix 
(Life  Technologies), and analyzed  using an  ABI  Prism  7500  Sequence  Detection  System 
(Applied  Biosystems,  Foster  City,  CA).  Transcription levels  of Muc5ac, Gob5, Ifnb, and 
RSV-G, RSV-F, and RSV-N were asesed  using custom SYBR primers, as previously 
described.160 Xbp1s and Xbp1us were asesed  with the folowing custom mouse-specific 
SYBR  primers: Xbp1sF:  5’-CTGAGTCCGAATCAGGTGCAG;  Xbp1s/usR:  5’-
GTCCATGGGAAGATGTTCTGG; Xbp1usF: 5’-CAGCACTCAGACTATGTGCA. The 
cycling threshold value  of the endogenous control gene, Gapdh,  was subtracted from the 
cycling threshold (∆CT). Expresion  of target genes is  presented as fold change (∆) values 
relative to an uninfected, untreated, or wild-type (WT) control group (2-∆∆CT), asigned an 
arbitrary value of 1. 
 
Transfection and RNA interference 
Smal interfering RNAs (Dharmocon, Lafayete, CO: L-049440-00-0005, siSIRT1; 
D-001810-10-05, siControl) were introduced via electroporation at  20 µM/sample 
according to manufacturer's instructions with an Amaxa Nucleofector Kit and Nucleofector 
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II Device (LonzaCologene, Cologne, Germany). Transfection eficacy was verified by qPCR, 
demonstrating  75-96%  decrease in Sirt1 expresion.  Viability  of cels after  48  h  post-
transfection, while maintained in DC growth medium, was ≥80% and not diferent from the 
transfection control cels. 48 h post-transfection, the DCs were infected with RSV for 2 h. 
 
Immunoprecipitation and immunoblotting 
Treated BMDCs were washed with PBS and treated with RIPA Lysis Bufer (#9806, 
Cel  Signaling Technology) supplemented  with  PMSF (Sigma-Aldrich) for  30 min on ice, 
vortexed for  1 min at  15-min mark.  After maximum centrifugation for  10  min, the 
supernatant was saved as whole cel lysate (WCL, input) and for immunoprecipitation (IP). 
For IP, cel lysates  were mixed  with acetyl-Lysine antibodies (#9441) at  4ºC  overnight 
folowed by the addition of Protein A–Sepharose 4B beads (1:100 Life Technologies) for 2 h 
at 4°C. Immune complexes were washed 3x with lysis bufer. After boiling in NuPAGE LDS 
Bufer and Reducing Agent (Life Technologies), samples were run on NuPAGE precast gels 
(Life Technologies) and transfered to nitrocelulose by an iBlot Dry Transfer System (Life 
Technologies). Membranes were blocked with 5% milk or BSA (Sigma-Aldrich) in 1x TBST 
(10x TBS (Corning, Manasas, MA) + 0.1% Tween) at RT, incubated with the indicated 1º 
antibodies overnight at 4ºC (Table 2.2), washed 3x in TBST, and finaly incubated with the 
appropriate horseradish peroxidase-conjugated 2º antibodies for 1-2 h RT (Table 2.2). Bands 
were visualized  by chemiluminesence (SuperSignal  West  Femto, Life  Technologies) on a 
Bio-Rad Imager. As  necesary,  blots were stripped  with  Restore  Stripping  Bufer (Life 
Technologies). Captured gel images  were inverted and saved as .tif files using Image  Lab 
software (Bio-Rad). To calculate mean intensity of fluorescence (MIF), images were opened 
in  Adobe  Photoshop  CS  6.0, transformed into gray scale, and rotated to level the  bands. 
Using an identical marquee box, bands were sequentialy selected to record the MIF of the 
histogram function. Mean  background was calculated as the  MIF  of the area immediately 
below each  band.  Background  was subtracted from each respective MIF value, and the 




Reagent Company and Catalog # Dilution 
Acetylated-Lysine polyclonal Ab Cel Signaling, #9441 1:100 
Acetylated-Lysine rabbit mAb (HRP conjugate) Cel Signaling, #6952 1:1000 
β-actin anti-mouse mAb Sigma-Aldrich A2228 1:5000 
Sirt1 rabbit anti-mouse mAb Cel Signaling, #3931 1:500 
Atg-5 Rabbit mAb Cel Signaling, #8540 1:1000 
Atg-7 Rabbit mAb Cel Signaling, #2631 1:1000 
LC3A/B Rabbit polyclonal Ab Cel Signaling, #4108 1:500 
Goat anti-mouse IgG-HRP (2º) Santa Cruz Biotechnology, sc-2031 1:50,000 
Goat anti-rabbit IgG-HRP (2º) Santa Cruz Biotechnology, sc-2004 1:2000 
Anti-biotin, HRP-linked Ab Cel Signaling, #7075 1:50,000 
Biotinylated Protein Ladder Cel Signaling, #7727  
EZ-Run pre-stained Rec Protein Ladder Fischer Scientific, #BP3603500  
Table 2.2: Antibodies and ladders used for immunoblotting. 
 
Confocal microscopy 
LC3 staining: BMDCs  were cultured as  described, and then  plated in  Lab-Tek 
chamber slides (Thermo  Fisher  Scientific,  Waltham,  MA).  Cels  were treated as indicated, 
washed in PBS, fixed in 4% paraformaldehyde for 20 min, and then blocked for 1 h at room 
temperature (RT) in  PBS  +  5%  normal goat serum  +  0.1%  Tween-20.  Cels  were 
subsequently incubated with 1º antibody rabbit polyclonal anti-LC3B (NB600-1384, Novus 
Biologicals, Litleton, CO) for 2 h at 37ºC, and then incubated with 2º antibody goat anti-
rabbit  Alexafluor  568 (A11011, Life  Technologies).  ProLong  Gold antifade reagent  plus 
DAPI (Life Technologies) was added before the cels were imaged on a Nikon A1 Confocal 
Laser  Microscope system  under  oil immersion,  using  NIS  Elements acquisition software 
(Nikon Instruments).  The  number  of  LC3  puncta/cel  was counted in at least  15 
cels/sample/condition/experiment. Images were converted to B&W in Adobe Photoshop to 
easily distinguish background staining from actual puncta. 
Caspase-3 staining:  After  2  h  of  HBSS-induced starvation  or  RSV-infection,  2 
drops/mL of  Caspase 3/7 Green  ReadyProbe (Life  Technologies) were added to each Lab-
Tek. Cels were washed, fixed, and incubated with ProLong Gold, as described above.  
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Transmission electron microscopy (TEM) 
Cels  were spun  down into a gelatin capsule  with a clinical centrifuge.  Cel  pelets 
were fixed in 4% gluteraldehyde in 0.1 M cacodylate bufer (pH 7.4) at 4ºC for 1 h. The cel 
pelets were washed 2x in 0.1 M cacodylate bufer, postfixed with 2% Osmium tetroxide for 
1  h  on ice and then rinsed  2x  with  0.1M cacodylate  bufer.  The fixed cel  pelets  were 
dehydrated through an ethanol (ETOH)  dilution series  up to  100%  ETOH and then 
immersed in propylene oxide (PO) for 10 min 2x. Next, pelets were infiltrated in a 1:3 (1 
h), 1:1 (2 h), and finaly 3:1 (overnight) eponate resin: PO mixture while rotating at RT, and 
subsequently embedded in 100% Eponate resin in gelatin capsules and alowed to harden in 
a 65ºC oven overnight. After hardening, tisue blocks were ultra-thin-sectioned at a 70 nm 
thicknes and  placed  on  200  mesh copper grids.  Grids  were counterstained  with saturated 
uranyl acetate and lead citrate and then viewed on a Philips CM-100 electron microscope. 5 
grids, ~ 15-20 cels/grid, were studied per treatment. 
 
Flow cytometry 
Right lungs of control and RSV-infected mice were digested enzymaticaly in RPMI-
1640 complete  media containing  1  mg/mL  Colagenase  A (Roche  Applied  Science, 
Indianapolis, IN) and  30 µg/mL  DNase I (Sigma).  BMDCs  were  washed from culture 
treatment.  Cels  were incubated with  Live/Dead  Fixable  Yelow (Life  Technologies) for  30 
min on ice, blocked with anti-CD16/CD32 for 20 min RT with gentle shaking, and stained 
for  20 min  RT with gentle shaking with appropriate antibodies as indicated in Table 2.3. 
Flow-Count Fluorospheres (Beckman Coulter, Pasedena, CA) were added right before flow 
cytometry to quantify absolute cel counts. Data were colected on a BD Biosciences LSR II 
flow cytometer and  on a  BD  Biosciences  FACS  Aria, and analyzed  using  FlowJo software 
(Treestar Inc, Ashland, OR). 
 
Sorted pulmonary cel populations 
Pulmonary  CD11b+ DCs,  CD103+ DCs, and alveolar  macrophages  were isolated 
from lungs/bronchi  of Sirt1f/f-CD11c-Cre± mice by enzymatic  digestion as  previously 
published.225 Briefly, minced tisue was incubated in RPMI-1640 with 200 µg/mL Liberase 
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TM (Roche Applied Science, Indianapolis, IN) and 200 U/ml DNase I (Sigma-Aldrich) for 
45 min at  37°C,  drawn through an  18-gauge  needle/10cc syringe, and filtered through  40 
µm  nylon  mesh.  The cel suspension  was enriched for  CD11c+ cels  using anti-mouse 
CD11c+ microbeads and  magnetic column separation (Miltenyi  Biotec); stained  with anti-
CD11b, anti-CD103, and anti-SigF antibodies (Table 2.3,  Lung  Sort); and finaly sorted 
with an iCyt Synergy 3200 cel sorter (iCyt, Champaign, IL). 
Antibody Conjugate Company Catalog # Dilution Purpose 
Ly6C PE BioLegend 128008 1:400 Lung Sort 
CD103 APC BioLegend 121414 1:200 Lung Sort 
MHCII Alexa Fluor 700 BioLegend 107622 1:1000 Lung Sort 
CD11c APC-Cy7 BioLegend 117324 1:200 
Lung Sort 
BMDC Sort 
CD11b eFluor 450 eBioscience 48-0112-82 1:400 
Lung Sort 
BMDC Sort 
CD3 PE BDPharmigen 553063 1:200 Lung Sort 
B220 PerCP-Cy5.5 BDPharmigen 552771 1:200 Lung Sort 
CD19 APC BioLegend 115512 1:200 Lung Sort 
CD4 APC-Cy7 BioLegend 100414 1:200 Lung Sort 
CD8α Pac Blue BioLegend 100725 1:200 Lung Sort 
ILR5α PE BDPharmigen 555902 1:200 Lung Sort 
Ly6G PE-Cy7 BDPharmigen 560601 1:400 Lung Sort 
Siglec-F (SigF) PE BDPharmigen 552126 1:200 Lung Sort 
CD11b PerCP-Cy5.5 BDPharmigen 550993 1:200 Splenic Sort 
CD11c APC BDPharmigen 550261 1:200 Splenic Sort 
CD4 PE-Cy7 BDPharmigen 552775 1:200 Splenic Sort 
CD8 Alexa 700 eBioscience 56-0081-82 1:200 Splenic Sort 
B220 APC-Cy7 BioLegend 103224 1:200 Splenic Sort 
CD115 PE eBioscience 12-1152-83 1:200 Splenic Sort 
CD40 PE BDPharmigen 553791 1:200 BMDC Sort 
CD80 PerCP-Cy5.5 BioLegend 104722 1:200 BMDC Sort 
CD86 PE-Cy7 BioLegend 105014 1:200 BMDC Sort 
MHCII APC eBioscience 17-5321-82 1:1000 BMDC Sort 
CD16/32 - BioLegend 101302 1:200 Al 
Live/Dead - Life Technologies L-34968 1:2000 Al 
Table 2.3: Antibodies for mouse flow cytometry and flow sorting. 
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Cel apoptosis assay 
The extent  of  necrosis and apoptosis in RSV-infected Sirt1f/f-CD11c-Cre BMDCs 
was  determined  using Annexin-V-APC and  propidium iodide (PI). BMDCs  were infected 
1:1  with  RSV  2-20 for  2  h in a  96-wel culture  plate.  After thorough  washing, cels  were 
incubated with Annexin-V-APC (1:200) for 15 min at 25 °C in the dark, washed, incubated 
under the same conditions with PI (1:200), and asesed immediately on a BD Biosciences 
LSR II flow cytometer. Raw data was analyzed as described above. Viable cels are negative 
for  both  PI and Annexin-V; early stage apoptotic cels are  positive for Annexin-V and 
negative for  PI;  necrotic cels  were  positive for  PI and  negative for Annexin-V; late stage 
apoptotic cels are  positive for  both Annexin-V and  PI. Readings  were recorded as  mean 
fluorescence intensity (MFI). 
 
Statistics 
Al  data are  presented as  mean  ±  SEM.  Data  were evaluated and graphs  were 
generated  using  GraphPad  Prism software.  Statistical significance  was asesed  by  one-way 




SIRT1 regulates DC activation 
& autophagy-mediated processes 
 
Sirt1 is significantly upregulated in DCs during RSV infection  
In Chapter 1, we described the importance of SIRT1 immune function and several 
studies studying SIRT1 in the context  of  pulmonary  disease. To  determine  whether Sirt1 
regulates RSV-induced  disease, Sirt1 mRNA levels  were  measured in  RSV-infected 
C57BL/6J WT mice. Maximal Sirt1 expresion was observed 4 days post-infection (dpi) in 
lung tisue, coinciding with peak viral load (Figure 3.1).7 
 
 
Figure 3.1: Sirt1 is upregulated in a mouse model 
of  RSV infection. Lung  mRNA expresion  of Sirt1 in 
RSV-infected WT BL6 mice was obtained using qPCR and 
compared  with  naive controls.  Values represent  mean  ± 
SEM, 5 mice per group. 
 
 
We next asesed whether there were cel-specific diferences in Sirt1 expresion. Sirt1 
mRNA levels  were examined in: mouse  BMDCs;  primary  mouse  pulmonary  DC subsets; 
primary  mouse alveolar  macrophages;  human  monocyte-derived  DCs; two immortalized 
pulmonary epithelial cel lines, MLE and LA4; and primary mouse AECs (Figure 3.2A-E). 
While al cel  populations showed increased Sirt1 expresion  over  untreated controls, the 
DCs  had the  highest increase (BMDCs  ~400-fold;  pulmonary  DCs and  hDCs:  ~4-fold). 
Additionaly, Foxo3 expresion rose in sync  with Sirt1 in  RSV-infected  DCs, supporting 
SIRT1’s roles in celular  metabolism and stres response (Figure 3.2A).  Due to the central 
role of DCs in directing immune responses, these cels became the focus of our studies. 
























Figure 3.4: Inhibition of SIRT1 attenuates autophagy in RSV-infected DCs. (A) Number 
of autophagosomes in WT BL6 BMDCs by 2 h post-RSV 2-20 infection (R) ± 1 µM EX-527 (E) or ± 10 
µM SRT1720 (S) was asesed by punctate LC3 staining and confocal microscopy (scale bar = 10 µm); 
data was quantified in (B) compared to respective controls.  Data are representative  of  2 independent 
experiments, 3 replicates/group. Values represent mean ± SEM. **p < 0.01. ***p < 0.001. 



























To further explore SIRT1’s promotion of autophagy, DCs were depleted of SIRT1 
using Sirt1-specific siRNA.  Examination  by confocal  microscopy  demonstrated that, in 
presence  of Sirt1 siRNA, fewer autophagosomes  were found in  RSV-infected  BMDCs 
(Figure 3.5A, B). Additionaly, Sirt1 knockdown significantly downregulated Ifnb expresion 
during RSV infection and reduced the levels of other innate cytokines, Il1b and Ccl5 (Figure 
3.5C). Overal, these results ilustrate that SIRT1 is crucial for efective autophagy-
dependent DC-activation using both pharmacological and siRNA knockdown approaches. 
 
Figure 3.5: Repressed autophagy and autophagy-dependent innate cytokine production 
in Sirt1 siRNA-treated BMDCs. (A)  WT  BL6  BMDCs  were transfected  by electroporation  with 
appropriate siRNA 48 h prior to RSV 2-20 infection (MOI 1:1). 2 h later, autophagosomes were observed 
by confocal microscopy, and quantified in (B). Scale bar = 10 µm. (C) Innate cytokine gene expresion 
asesed by qPCR in WT BL6 BMDCs 24 h post-RSV infection. Cels were transfected with control or 
Sirt1-specific siRNA  48  h  prior to infection.  Data are representative  of  2 independent experiments,  3 
replicates/group. Values represent mean ± SEM. *p < 0.05. **p < 0.01. ***p < 0.001. 
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DCs from Sirt1f/f-CD11c-Cre+ mice  have  altered  cytokine  production 
and autophagy in response to RSV 
To investigate the role of Sirt1 within DCs during RSV-induced responses in a more 
physiologic seting, we generated conditional knockout mice (Sirt1f/f-CD11c-Cre), where the 
Cre+ progeny expres catalyticaly inactive SIRT1 in CD11c+ myeloid cels. We verified Sirt1 
excision in  Cre+ BMDCs (Figure 3.6A).  We also  observed  no  baseline  diferences in the 
number of pulmonary immune cel subtypes from naive Sirt1f/f-CD11c-Cre mice or in splenic 
cel subsets from RSV-infected Sirt1f/f-CD11c-Cre mice (Figure 3.6B-D). 
Figure 3.6:  Characterization  of Sirt1f/f-CD11c-Cre mice. (A)  DNA from  Day  10  BMDCs 
cultured from  DC-Sirt1 KO  mice  was extracted,  purified,  PCR amplified, and finaly separated  by  2% 
agarose gel.  The top row ilustrates the expected excision  band created  using  primers flanking the Sirt1 
exon 4 excision site in Cre+ mice and the absence of this excision band in Cre- mice. Note the negligible 
amount of Sirt1 exon 4 DNA in Cre+ BMDCs. Data representative of >5 independent samples. (B,  C) 
Total  numbers  of  pulmonary immune cel  populations  obtained from colagenase-digested lungs  of 3 
naive  WT  BL6, 3 Sirt1f/f-CD11c-Cre−,  or 3 Sirt1f/f-CD11c-Cre+ mice, as  determined  by flow cytometry. 
(D) Flow cytometric analysis of the total numbers of DC and T-cel populations isolated from the spleens 




Recently it  has  been reported that  LC3 can  be recruited to  other  membranes, 
including single-membrane vesicles, in a  proces  known as  LC3-asociated  phagocytosis 
(LAP).508 While  LAP and autophagy  both  produce  punctate  LC3 immunostaining, a  key 
distinguishing  ultrastructural feature  between these  proceses is the formation  of a single 
versus  double-waled vesicle.244 To verify that the Sirt1-deficient  DCs  were  not forming 
autophagosomes, starved  or  RSV-infected  Cre− and  Cre+ BMDCs  were examined  by 
transmision electron microscopy (TEM). Double-waled and single-waled membranes were 
observed in  Cre− BMDCs at  baseline, after starvation, and after  RSV infection,  whereas 
double-waled autophagosomes or autolysosomes were undetected in Sirt1-deficient BMDCs 
under the same conditions (Figure 3.9). These TEM data validate the confocal microscopy 
data that the formation of autophagosomes was severely impaired in Cre+ DCs. 
 
Figure 3.9: Ultrastructural  analysis  of BMDCs from Sirt1f/f-CD11c-Cre mice  during 
stress  conditions. Representative  TEM images  of  Cre− and  Cre+ BMDCs,  which  were  untreated 
(media only), starved with HBSS medium, or infected with RSV 2-20 for 2 h. Scale bar = 100 nm. Note 
the  double-membranes in the insets (Cre− panel).  Thick arrowheads indicate autophagosomes.  The star 
indicates the initiation  of an autophagosome,  with an isolation  membrane  beginning to encompas 
cytosolic material. Thin arrowheads indicate single-membrane vacuoles, some containing celular material. 
5 grids, ~ 15-20 cels/grid, were studied per treatment. 
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Interestingly, several autophagosome-engulfed mitochondria were observed in RSV-
infected  Cre- BMDCs (Figure 3.9). The absence  of  mitophagy in the  Cre+ BMDCs in the 
presence of RSV was striking, given the necesity of eliminating damaged mitochondria.253, 
353 As cel  death is a common response to  unresolved cel stres, studies to visualize 
mitochondrial-caspase activation were  performed. During nutrient starvation  or  RSV 
infection, Cre+ BMDCs contained greater staining for active caspase 3/7, an early indication 
of apoptosis, suggesting that the cels were  destined for cel  death (Figure 3.10).  However, 
cel analysis by flow cytometry revealed equal proportions of Cre- and Cre+ BMDCs destined 
for  death after  RSV infection (Figure 3.11). Thus,  while Sirt1-deficient  DCs appear to 
respond negatively to nutritional or viral stres, their survival is not altered. 
 
Figure 3.10:  BMDCs from Sirt1f/f-CD11c-Cre+ mice express  more  activated  caspase  3 
during stress conditions. Caspase  3/7 staining in  Cre− and  Cre+ BMDCs  2  h after  no treatment 
(media  only),  HBSS treatment (starvation  medium),  or  RSV  2-20 infection (MOI  1:1), visualized  by 






Figure 3.11: The  deficiency  of  SIRT1 
does not alter cell survival during RSV 
infection. Annexin-PI flow cytometric 
analysis of cel death in BMDCs isolated from 
Sirt1f/f-CD11c-Cre mice 24  h after  RSV  2-20 
infection (MOI 1:1). Data are representative of 
2 independent experiments. Values represent 
MFI fractions ±  SEM,  3 replicates/group. No 
significance between groups. See Chapter 2 for 
detailed characterization of these death stages. 
 
APC function is not SIRT1-dependent 
Atenuation  of cytokine  production and autophagy in the absence  of functional 
SIRT1 prompted APC function studies. As described in Chapter 1, DCs promote adaptive 
immune responses by stimulating  naïve and  RSV-reactive  memory  T cels in the  LN via 
cytokine production, co-stimulation, and antigen presentation. Flow cytometric studies were 
used to examine SIRT1’s afect on the expresion of DC maturation markers (CD40, CD80, 
CD86),  which serve as co-stimulatory  proteins for  T cel activation. BMDCs from Sirt1f/f-
CD11c-Cre± mice equaly upregulated the expresion of these surface proteins in response to 
RSV (Figure 3.12). Thus, while SIRT1 significantly afects DC cytokine production during 
viral infection, it is not necesary for APC co-stimulatory marker expresion. 
 
Figure 3.12:  SIRT1  does  not 
influence the  expression  of  DC 
maturation  markers. Surface  maturation 
(co-stimulatory) marker expresion by Cre- or 
Cre+ BMDCs, isolated from Sirt1f/f-CD11c-
Cre mice, as measured by flow cytometry 24 
h after RSV 2-20 infection (MOI 1:1). Data 
representative of 4 independent experiments. 
Values  = MFI  ±  SEM,  3 replicates/group. 
Stars indicate significance compared to 
respective naïve controls. **p < 0.01. 
 
This  observed  proficiency in DC co-stimulatory  marker expresion was tested in 
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APCs and  T cels,  were stimulated  with an antibody against  CD3, a  T cel co-receptor 
necesary for transmiting activation signals. In this  manner, we could  observe the co-
stimulatory function  of the Cre- and  Cre+ splenic  DCs in the  presence  of a strong  TCR 
stimulus. Figure 3.13 shows no diferences in T cel cytokine production between Cre- and 
Cre+ splenic whole cel cultures. Therefore,  SIRT1 is  neither  necesary for  APC co-
stimulatory marker expresion nor for T cel co-stimulation. 
 
 
Figure 3.13: T cell  co-stimulation is 
not  dependent  on  SIRT1. Cel cultures 
from  whole spleen, prepared from Sirt1f/f-
CD11c-Cre± mice, were stimulated  with 2 
µg/mL of anti-CD3 for 72 h. T cel cytokine 
concentrations  were  measured  by  Bio-Plex 
asay.  Values represent  mean  ±  SEM,  5 




Finaly, to directly evaluate the antigen presentation capacity of DCs that harbored 
dysfunctional SIRT1, co-cultures of DCs and T cels were performed. In the presence of the 
SIRT1 chemical inhibitor,  EX-527, BL6  RSV-infected BMDCs retained the capacity to 
present viral antigen to  RSV-specific CD4+ T cels (Figure 3.14A). To analyze the  APC 
function in context of Sirt1-deficiency, Sirt1f/f-CD11c-Cre± BMDCs were co-cultured with 
OVA-specific or RSV-specific CD4+ T cels. Despite some inconsistency in IL-4 production, 
T cels were equally stimulated regardles of the status of SIRT1 in DCs (Figure 3.14B, C). 
These data reveal that even in the absence of functional SIRT1, DCs are proficient at antigen 
presentation. 



















Figure 3.14: Sirt1-deficient  DCs retain the  capacity to  present  antigen to  T  cells. (A) 
CD4+ T cels were purified from mediastinal LN of BL6 RSV-infected mice, 8 dpi. Cels were plated at a 
10: 1 ratio over ± EX-527-treated BMDCs, infected 2 h previously with 1:1 MOI RSV. (B) An equivalent 
experiment as in (A)  using Sirt1f/f-CD11c-Cre± BMDCs instead  of  EX-527. (C) Sirt1f/f-CD11c-Cre± 
BMDCs were pulsed with whole OVA protein folowed by the addition of 10:1 purified splenic OT-II 
CD4+ T cels. Cytokine concentrations in culture supernatants were asayed at 48 h by Bio-Plex. Results 
are representative of at least two independent experiments. Unles indicated, stars represent significance as 
compared to T cel + OVA controls. *p < 0.05. **p < 0.01. ***p < 0.001. 
Summary 
Chapter  3 focused  primarily  on  SIRT1’s influences  on celular  proceses that are 
critical for DC function during RSV infection. As antigen-presenting cels (APCs), DCs are 
responsible for T cel diferentiation and maturation, and the T cel response in turn shapes 
the pulmonary immune environment. Activated DCs provide two signals required for 
succesful T cel activation: antigen presentation via MHC molecules (to stimulate the TCR) 
and co-stimulatory  marker  presentation (to stimulate the  T cel receptors  CD28L and 
CD40). In the  presence  of  TCR stimulation alone,  T cels  undergo apoptosis  or enter an 
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inactivated state caled anergy.509 DC-specific cytokines provide a third instructive signal to 
activated T cels, fine-tuning the adaptive immune response to the invasive pathogen. 
EX-527-inhibited and Sirt1f/f-CD11c-Cre+ DCs displayed a  unique, altered 
phenotype, which included atenuated cytokine production and autophagy in the seting of 
undisrupted antigen presentation and  T cel co-stimulation. These findings suggest that 
SIRT1 enhances autophagy-dependent cytokine production in DCs, but does not influence 
the esential APC signals necesary for efective T cel activation. Likewise, this suggests that 
SIRT1 is  necesary  but  not suficient for autophagy, as some autophagosomes  were stil 
detectable in  SIRT1-inhibited  or Sirt1-deficient  DCs. In contrast,  our laboratory  has 
previously shown that inhibition or knockdown of autophagy in RSV-infected DCs prevents 
DC maturation, decreases cytokine production, and disrupts antigen presentation.233 
Given that cytokines provide critical communication signals between efector cels 
and APCs, we hypothesized that this observed deficiency in DC cytokine production would 
alter the overal immune response in vivo. To  more thoroughly understand the impact  of 
DC-specific Sirt1 dysfunction on both innate and adaptive immunity, we performed studies 




SIRT1 promotes the development of efficient 
antiviral immune responses during RSV infection 
 
Systemic inhibition of SIRT1 augments RSV-induced lung pathology 
To test whether Sirt1 modulated the outcome of RSV infection, C57BL/6J WT mice 
were infected with RSV on day 0, and received daily intraperitoneal injections of EX-527 (1 
mg/kg), a  SIRT1-selective chemical inhibitor.  At  8  dpi, a time  point that coresponds to 
maximum lung  pathology,42 the animals  were sacrificed to ases  pathological  parameters. 
Histological examination  of lung sections from  RSV-infected  mice revealed greater  peri-
bronchial inflammation (Figure 4.1A) and goblet cel hyperplasia (Figure 4.1B) in EX-527-
treated,  RSV-infected lungs than in infected controls.  Gene expresion analysis revealed 
similar upregulation of mucus-related genes, Muc5ac and Gob5, in response to RSV infection 
regardles  of  EX-527 treatment (Figure 4.1C). There  were significant increases in the 
expresion  of Ifng, Il5, and Il10 in the  EX-527-treated,  RSV-infected  mice compared to 
control  RSV-infected  mice (Figure 4.1D). The increased  mRNA levels  of  RSV  proteins in 
the EX-527-treated, RSV-infected animals suggested that viral clearance was reduced in the 
absence  of functional  SIRT1 (Figure 4.1E).  RSV-restimulated lymph  nodes from the  EX-
527-treated, RSV-infected mice produced significantly higher levels of the Th2 cytokines IL-
4, IL-5, and IL-13 than RSV-infected controls (Figure 4.1F), with no diferences in IL-17a 
or IFNγ production.  Therefore, this in vivo study  demonstrates that systemic  SIRT1 
inhibition exacerbates RSV-induced lung pathology and alters the cytokine milieu within the 




Sirt1f/f-CD11c-Cre+ mice  experience  exacerbated lung  pathology  and 
delayed resolution of inflammation folowing RSV infection  
During the first three days of RSV infection the host response is dominated by innate 
immunity.  This response includes the activation  of resident  DCs, the secretion  of early 
inflammatory mediators, and the recruitment of Natural Kiler cels and neutrophils.42 Since 
DC influx  begins as soon as  2  dpi,186 we  used this time  point to analyze early immune 
responses to RSV in Sirt1f/f-CD11c-Cre mice. There were significant increases in lung mRNA 
levels  of  potentialy  pathogenic cytokines Il13, Il17a, and Il10 in  Cre+ mice compared to 
Cre− mice (Figure 4.2). Additionaly, crucial innate cytokines, including Il6, Il12p40, and 
Tnfa,  were  downregulated in the lungs  of  Cre+ mice  post-infection, recapitulating  our in 
vitro observations in DC subsets. Overal, at 2 dpi, immune cels were infiltrating the lungs 
in similar proportions (Figure 4.3, top right). 
 
Figure 4.2: RSV-infected Sirt1f/f-CD11c-Cre+ mice  develop  a pro-inflammatory lung 
immune  environment by  2  dpi. Gene expresion  of lung cytokines  2  dpi  with  RSV  2-20  was 
obtained  using  qPCR and compared  with  naive controls.  Data representative  of  2 independent 
experiments, 3-5 mice/group, values = mean ± SEM. *p < 0.05.  
To specificaly examine the impact  of Sirt1 deletion in  CD11c+ APCs  during the 
height of RSV-induced lung pathology, we analyzed Sirt1f/f-CD11c-Cre+ mice and litermate 
controls  8  dpi.  Histological examination revealed that  Cre+ mice  had increased levels  of 
airway inflammation and goblet cel  hyperplasia compared to  Cre− controls (Figure 4.3, 
botom left). RSV-infected Cre+ mice expresed higher levels of pathogenic cytokine genes, 






















Figure 4.3: Increased inflammatory infiltrates  and  mucus  production in  airways  of 
RSV-infected Sirt1f/f-CD11c-Cre+ mice. Representative lung histology from naive and RSV 2-20-
infected Sirt1f/f-CD11c-Cre mice  2,  8, and  12  dpi stained  with  hematoxylin and  PAS. Insets  highlight 
goblet cel hyperplasia. Note the mucus plug occluding the Cre+ airway 12 dpi. Scale bar = 100 µm. Data 




Alveolar macrophages are unique amongst other macrophages located throughout the 
body in that they expres high levels of CD11c. To verify that the observed RSV immune 
responses were in fact due to DC-specific dysfunction, we sorted primary macrophages from 
the lungs of Sirt1f/f-CD11c-Cre mice. Unlike the significant decrease in cytokine production 
in  CD11b+ pulmonary  DCs upon  RSV infection (Figure 3.7), alveolar  macrophages were 
stil able to eficiently upregulate inflammatory cytokines  during ex vivo RSV stimulation 
(Figure 4.6). Therefore, Sirt1-deficiency in alveolar  macrophages is likely  not relevant in 
these in vivo experiments, especialy given that DCs are the superior  APCs responsible for 
mediating the resultant  T cel response. Overal, the results  of the conditional  KO  mouse 
studies paralel the results of our EX-527 studies, and support the concept that Sirt1 in DCs 




Figure 4.6:  RSV-infected  CD11c+ alveolar  macrophages from Sirt1f/f-CD11c-Cre+ mice 
are  proficient  at inflammatory  cytokine  production. CD11c+ macrophages were flow sorted 
from lungs of naive Cre− or Cre+ mice prior to ex vivo RSV infection. Innate cytokine gene expresion 24 
h post-RSV 2-20 (MOI 1:1) infection was obtained by qPCR. Data are representative of 2 independent 
experiments. Values represent mean ± SEM, 3 replicates/group, 5 mice/sort. *p < 0.05.  
 
SIRT1 does not alter RSV gene expression within DCs 
In the aforementioned  mouse experiments, there were greater increases in viral 
transcript  within the airways  of  EX-527-treated  or  DC-specific Sirt1-deficient  mice over 
infected controls (Figure 4.1E, Figure 4.4D).  This we atributed to a  poorer immune 
response, which resulted in reduced viral clearance. As discused in Chapter 1, a recent study 
has described SIRT1 as a viral restriction factor, capable of inhibiting replication of several 























directed immune responses important for eficient viral clearance, rapid resolution  of 
pulmonary inflammation, and minimal damage to adjacent healthy tisue. 
Sirt1f/f-CD11c-Cre+ mice displayed elevated viral gene expresion levels in their lungs 
compared to  Cre- animals, indicating either excesive viral replication  or retention  of viral 
antigens within DCs, likely due to a decrease in autophagy. As Sirt1-deficient DCs harbored 
no apparent defects in T cel activation, as discused in Chapter 3, the lack of eficient viral 
resolution suggests that the miscommunication  between the  APCs and efector  T cels is 
primarily a result of poor DC cytokine production. Therefore, while not necesary for T cel 
diferentiation and  maturation, DC-made cytokines are significant in instructing the 
adaptive immune response,  which in the absence  of functional  SIRT1 within DCs was 
skewed towards a pathological Th2/Th17 response. 
Interestingly,  our results are contrary to the  previous studies,  which suggest  SIRT1 
programs  DCs to  promote pathological inflammatory immune responses.454, 455 In  one 
experiment,  DC-specific Sirt1 KO  mice  were resistant to chemicaly-induced EAE, 
exhibiting a significant reduction in central nervous system pathology, much fewer Th17 and 
Th1 celular infiltrates, and a significant increase in  Tregs.454 Another study demonstrated 
that the lack of SIRT1 in DCs reduced innate immune cel infiltrates in the airways of mice 
during OVA-induced asthma.455 The data suggest that SIRT1 promotes DC maturation and 
pro-Th2 skewing activity. Likewise, upon treatment with pharmacological SIRT1 inhibitors, 
these  DC-specific Sirt1 KO  mice experienced reduced  Th2 responses and  were  protected 
against alergic airway inflammation.455 Of  note, these contradictory results to  our  EX-527 
study  may  be  due to the  diferential specificity  of the  SIRT1 inhibitors.  Overal, our  RSV 





Discussion, Conclusions, & Future Directions 
 
As  discused in  Chapter  1, adults often mistake an  RSV infection for the common 
cold, most experiencing only mild  upper respiratory tract symptoms.  However, this  highly 
infectious virus is the principle cause  of LRTI among  neonates and children, predisposing 
these young patients hospitalized  by an  RSV infection to  develop recurent  wheezing and 
asthma later in life.3-5, 43-48 Additionaly, RSV contributes significantly to the morbidity and 
mortality among the elderly, the immunocompromised, and those living  with  pulmonary 
dysfunction, such as in the case of alergic asthma or COPD.3-5 Overal, the complications of 
severe RSV infection suggest that the host antiviral immune response, and the subsequently 
altered  pulmonary environment, facilitate the genesis and exacerbation  of chronic airway 
disease. Alas, an efective, safe vaccine or an afordable, widely accesible treatment has yet to 
be synthesized. Therefore, studies aimed at further elucidating the RSV-host immune system 
interaction are imperative to the development of succesful pharmacologic therapies. 
The deacetylase SIRT1 is a  ubiquitous  protein that impacts numerous areas of 
biology and  pathophysiology, including stres responses,  development,  metabolism, 
cardiovascular  disease, cancer,  neurodegeneration, inflammation, and immunity.377, 390-393 
While  SIRT1 regulates immune responses such as lymphocyte activation,  proliferation, 
diferentiation, and  macrophage cytokine secretion,390 its role in  DC biology has yet to  be 
elucidated. Given the significance  of  DCs in  dictating innate immunity and  priming 
adaptive immune responses, the unknown function of SIRT1 in DCs prompted the studies 
described in Chapter 3 and 4. Our results shine new light on SIRT1’s complex relationship 
with various celular pathways (i.e. autophagy) and disease-related proceses (i.e. respiratory 
viral infections). 
 82 
SIRT1 promotes  DC-mediated antiviral immunity  and limits  RSV-
induced pathology 
Appropriately activated  APCs are instrumental in achieving immune responses that 
efectively clear an infection  while limiting injury to surounding tisue. The studies 
addresed in this disertation indicate that SIRT1 is necesary to promote DC activation and 
autophagy during RSV infection, and that in the absence of active SIRT1 within DCs, mice 
experience a pathological antiviral immune response. We have demonstrated the importance 
of SIRT1 in DC biology by three independent approaches: (1) chemical inhibition of SIRT1 
with  EX-527, (2) siRNA  knockdown  of Sirt1, and (3) genetic ablation  of Sirt1 in  DCs. 
Blocking Sirt1 by any  of these  methods resulted in atenuated cytokine  production and 
inhibited autophagosome  numbers within  RSV-infected  DCs. Additionaly, global 
inhibition of SIRT1 (EX-527) and conditional (CD11c+ cel-specific) Sirt1 deficiency in an 
RSV infection  model led to the exacerbation  of  pulmonary  pathology.  These later results 
suggest the adaptive immune response is skewed towards an alergic (Th2) phenotype in the 
seting of DC-specific Sirt1 deficiency. Furthermore, the decrease in viral clearance at 8 dpi 
may have contributed to the lack of resolution in pathology and inflammation at 12 dpi in 
Sirt1f/f-CD11c-Cre+ mice (Figure 4.5).  Thus, these  disertation experiments are the first to 
characterize Sirt1 as having a beneficial impact on an antiviral response, and to link Sirt1 to 
autophagy and innate cytokine activation  within viraly infected  DCs.  As summarized in 
Figure 5.1, these functions  of  SIRT1 appear to  have a significant role in  directing the 
development of an eficient antiviral, minimaly pathologic immune environment. 
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Figure 5.1: Sirtuin 1 promotes effective antiviral adaptive immune responses by driving 
DC  activation  and  autophagy. Upon  uptake  of viral antigens,  DCs  upregulate Sirt1 expresion. 
SIRT1 contributes to the activation of autophagic proceses within the DC, such as by deacetylating key 
ATG  proteins,  which indirectly  promote  APC function.  Likewise,  SIRT1  may  directly  promote  DC 
function (not elucidated), given its  broad involvement in  many celular  pathways.  Once activated,  DCs 
produce innate cytokines, skewing  T-cel  diferentiation toward an antiviral  Th1 adaptive immune 
response, while suppresing pathologic Th2 and Th17 responses. As a result, SIRT1 within DCs dictates 
the  development  of an immune environment that eficiently clears the  RSV and resolves the asociated 
inflammation.  
Previous  work  has revealed that  SIRT1 can  block immune and inflammatory 
proceses, including cytokine  production in  APCs,390, 484 likely  due to its transcriptional 
represion of NFκB (RelA/p65) via deacetylation.408 Furthermore, it has been demonstrated 
that the ablation of Sirt1 in macrophages, using a myeloid cel-specific Sirt1 knockout (Mac-
Sirt1 KO) mouse, rendered NFκB hyperacetylated and resulted in increased transcriptional 
activation  of  proinflammatory target genes, including Il6, Il12, Tnfa and Il1b.409 These 
researchers concluded that  by targeting  NFκB,  SIRT1 acts as a  brake  on  metabolicaly 
detrimental inflammatory cytokine production by macrophages in a model of diet-induced 
diabetes. However, during RSV infection, DCs depend on autophagy for the traficking of 
viral components to  mediate  TLR-induced innate cytokine  upregulation.  As evidenced in 
Chapter 3, the lack of SIRT1 in DCs reduced critical cytokine production, including IFNβ 
and IL-12,  which  we suggest contributed to a  pathological  Th2/Th17 immune response 
within the airways. Importantly, when DCs were stimulated with TNFα in the presence of 
EX-527, increased IL-6  production  was observed (Appendix 1). Thus, lack  of  SIRT1  does 
not intrinsicaly impair cytokine gene transcription and secretion. This preliminary data also 
suggests that  under certain stimuli,  SIRT1-inhibited  DCs  do  not rely  on autophagy-
mediated proceses, and that instead, blockade of SIRT1 leads to cytokine production driven 
by increased  NFκB acetylation. It  would  be interesting to explore gene expresion and 
activity levels  of the  NFκB signaling  pathway  within Sirt1-deficient  DCs  during  RSV 
infection.  Corolary studies could also include the  overexpresion of NFκB pathway 
components in the context  of  RSV infection, to  observe  whether this would  overcome 
atenuated cytokine production in Sirt1-deficient DCs. Two independent studies examining 
DC-specific Sirt1 KO mice have reported no changes in DC maturation, diferentiation, or 
development as compared to WT DCs,454, 510 in agreement with our observations examining 
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co-stimulatory  marker expresion and  DC immune  populations (Figure 3.6, Figure 3.12). 
However, in contrast to  our  TLR7 agonist results, one  of these studies demonstrated that 
Sirt1-/- DCs produced higher levels of cytokines upon TLR1, TLR4, or TLR3 stimulation.454 
Thus,  our  data indicate that  SIRT1  has a  unique role in  modulating  DC cytokine 
production in the context  of a viral infection, such as  RSV, that relies on autophagy-
mediated PAMP delivery to endosomal TLRs.511 
Sirt1-/- mice share  phenotypic similarities  with autophagy-defective Atg5-/- mice,373 
highlighting the significance of these proteins’ interactivity. Given that the lack of functional 
SIRT1 atenuated DC-specific autophagy (Figure 3.4, Figure 3.5, Figure 3.8), experiments 
were  performed to verify the previously reported physical interaction  between  SIRT1 and 
autophagosomal  proteins within  DCs.373 Overal, preliminary results suggest that levels  of 
acetylated-ATG proteins were increased or at least stabilized by EX-527 treatment, compared 
to  untreated controls, indicating the chemical inhibitor  was  blocking  SIRT1 activity (data 
not shown). During autophagosomal formation, the protein LC3 is proteolyticaly modified 
into  LC3II, and  upon vesicular  maturation LC3II is recycled. Bafilomycin can  block this 
maturation event  by inhibiting lysosomal acidification and thus autophagosome-lysosome 
fusion.244 Protein analysis  of RSV-infected DCs isolated from Sirt1 conditional KO  mice 
showed lower levels  of  LC3II/I,  LC3II, and  LC3I  protein ratios, suggesting a  decrease in 
autophagy flux (Appendix 2). These protein analyses recapitulate our observation that Sirt1-
deficient  BMDCs are stil capable  of low levels  of autophagosome formation upon  RSV 
exposure (Figure 3.8). Al together, it is posible that SIRT1 enhances autophagy flux, but it 
is not absolutely required. Further  biochemical studies should be conducted to thoroughly 
characterize SIRT1’s influence on the autophagosomal machinery.  
The significance  of  SIRT1 in regulating autophagy-related DC function can  be 
expanded to emerging studies on the  pathogenesis  of  neurodegenerative  diseases. Among 
these neuronal  diseases, such as  Alzheimer’s  disease,  Parkinson’s  disease, and  Huntington’s 
disease, the main pathological phenotype is the accumulation of toxic intracelular aggregates 
of mutant  proteins. Several  neurodegenerative  diseases  have  been asociated  with  defective 
autophagy, most in part caused by specific mutations in autophagy genes.252, 512 Additionaly, 
the evidence for  SIRT1’s  protective activity against  protein-aggregate-related 
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neurodegeneration is  quite expansive.  Thus, it is intuitive to  propose a crucial interaction 
between  SIRT1 and autophagy in  promoting  neuronal survival. We can speculate that in 
neurons susceptible to degeneration, a  dysfunction in autophagy is due to either low 
expresion or activity of SIRT1, defective autophagy proteins (as reported), or a combination 
of SIRT1 and autophagy  protein deficiencies. While there is active investigation into the 
independent contributions of SIRT1 and autophagy in the genesis and progresion of these 
diseases, it  would  be  highly enlightening to study these  proceses together. For example, a 
subset of Parkinson’s disease is linked to mutation in PARK2/Parkin.279 Do patients with this 
disease  mutation display reduced  SIRT1 activity? α-synuclein  has  been shown to interfere 
with  Parkin solubility and  distribution, contributing to the pathogenesis of  Parkinson’s 
disease.513 If  neuronal cels isolated from these individuals were treated  with  SIRT1 
activators,  would there  be a reduction in α-synuclein-mediated toxicity due to an 
upregulation  of autophagosome formation? Therefore, future studies focusing  on the 
interaction of SIRT1 and autophagy within neurons may yield fruitful discoveries that could 
contribute to cel survival in patients plagued with such neurodegenerative conditions.  
On the other hand, the interaction of SIRT1 and autophagy may also contribute to 
disease  pathology, such as during the chronic inflammation of rheumatoid arthritis (RA). 
This autoimmune  disease is characterized  by  persistent synovial hyperplasia and 
inflammation  due to immune infiltrates, leading to the  destruction  of joint cartilage and 
bone.514 Innate immunity  has  been shown to  be important in the  development  of chronic 
arthritis, including TLR and NLR activation within synovial cels, which leads to IL-6 and 
TNFα overproduction.515, 516 Of note,  TNFα-induced  overexpresion  of Sirt1 has  been 
reported to contribute to this chronic inflammation by promoting cytokine production and 
inhibiting apoptosis in  RA synovial fibroblasts.505 Interestingly,  knockdown  of Sirt1 by 
siRNA or inhibition  by EX-527  decreased  TNFα production in  human  monocytes and 
fibroblasts,505 much like  blocking  SIRT1 significantly reduced cytokine levels in  our  DCs. 
Likewise, independent studies  have noted that  TNFα promoted autophagy in  osteoclasts, 
enhancing their  bone resorptive capacity.517 Human synovial fibroblasts from  RA  patients 
displayed increased autophagy and  protection from apoptosis, thus contributing to their 
persistent inflammatory cytokine  production.518 This  begs the  question  whether there is a 
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feedback loop between SIRT1 and autophagy, in which enhanced SIRT1 activity contributes 
to aditional autophagy flux, leading to more  TNFα production. Therefore, the described 
relationship between SIRT1 and autophagy in our study suggests the posibility of a paralel, 
yet detrimental relationship in the context of RA. 
Tisue- and context-dependency of SIRT1’s efects may underlie the variability in the 
protein’s role in many diseases, including diabetes, cancer, and immunity. Data suggest that 
SIRT1 serves to dampen the pro-inflammatory nature of activated macrophages and T cels 
(Chapter 1), which paralel our in vivo results where mice experienced greater RSV-induced 
lung pathology and inflammatory cytokine production with EX-527 treatment (Figure 4.1). 
As  EX-527  was administered systemicaly, it is posible that the aggravated pathology  was 
due to a synergistic efect of global SIRT1 inhibition on multiple cel types, including AECs, 
alveolar  macrophages, and  T cels. However, this EX-527 in vivo data mirored the results 
obtained when DC-specific (CD11c+) Sirt1 KO mice were infected with RSV (Figure 4.3, 
Figure 4.4), highlighting the significance of SIRT1 dysfunction specificaly in DCs. Despite 
reports that  SIRT1  mediates  pro-inflammatory responses in  DCs,454, 455 we  observed an 
atenuation of DC cytokine production, but a retention of APC function, when SIRT1 was 
absent or defective (Chapter 3). Therefore, our in vivo experiments stres the esential role of 
SIRT1-mediated  DC cytokine  production during  RSV infection in fine-tuning the T cel-
mediated adaptive immune response. 
This modulating role and tisue-specificity of  SIRT1 is further exemplified in the 
seting  of metabolic  disease. In the case  of several family members diagnosed  with  Type  1 
diabetes due to a Sirt1 point mutation (SIRT1-L107P), their insulin-producing pancreatic β-
cels overproduced nitric oxide, the cytokines TNFα and IL-1β, and the chemokine CXCL1, 
a neutrophil chemoatractant.384 As a result, these patients sufered from hyperglycemia and 
insulin dependence, and they were positive for β-cel autoantibodies. The puzzling aspect of 
this  mutation is its location outside  of the conserved enzymatic core, which causes no 
changes in  protein stability, subcelular localization,  or protein-protein interactions with 
major binding partners. Therefore, the alteration in SIRT1’s ability to modulate the activity 
of specific  proteins  over a transient  period  of time in  pancreatic β-cels seems to cause the 
diabetic  phenotype  observed at the  organismal level. Perhaps in the  presence  of insulin 
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resistance due to SIRT1 dysfunction, stres accelerates β-cel death resulting in the release of 
autoantigens and endogenous “danger signals” capable of promoting pathologic self-antigen 
presentation.519 In this disease context, the ability of SIRT1 to suppres TNFα expresion452 
was  partialy ablated  by the  L107P  mutation,  which is significant given that TNFα 
antagonism has  been shown to improve diabetic symptoms.520 Thus,  SIRT1 fine-tunes 
insulin sensitivity by afecting cytokine production in β-cels, much as it modulates antiviral 
immunity by afecting cytokine production in DCs. 
Data discused in Chapter 4 alow for further speculation toward specific pulmonary 
disease states.  Baseline respiratory  dysfunction, as in the case  of chronic  obstructive 
pulmonary  disease (COPD) and alergic airway  disease (i.e. asthma), can  be exacerbated 
during RSV infection.5 Of note, cigarete smoke reduces the levels of SIRT1 in the lungs of 
patients  with  COPD and in rat  models, as  wel as in  monocyte-macrophage cel lines.521 
Perhaps  mechanisticaly related,  SIRT1  deacetylates target  proteins such as  FOXO3,  p53, 
matrix  metaloproteinase  9 (MMP  9), and  NFκB, al  of  which are implicated in the 
pathogenesis  of  COPD.521 Thus, reduction  of  SIRT1  may  promote acetylation  of these 
proteins, thereby enhancing  disease factors including autophagy, celular senescence, 
emphysema, fibrosis, and inflammation. Targeting SIRT1 in pre-clinical pulmonary disease 
models  has yielded  disparate results. In asthma  mouse  models, administration  of 
pharmacological sirtuin inhibitors (Sirtinol and  Cambinol) reduced alergic airway 
inflammation and  Th2 cytokine responses.455, 507 However, in a separate study  using the 
SIRT1 activator SRT1720, inhibition of Th2 responses was observed during OVA-induced 
airway disease.491 Thus, compared to our studies of RSV-induced responses, SIRT1 may have 
a  diferential efect in a  non-infectious seting.  These seemingly contradictory results  may 
also  be atributed to the specificity  of the inhibitors.  As  noted in  Chapter  1,  Sirtinol 
antagonizes SIRT2 more potently than SIRT1, while Cambinol inhibits SIRT1 and SIRT2 
with similar IC50 values. In contrast, EX-527 is a potent and selective SIRT1 inhibitor, with 
negligible potency against SIRT2 or SIRT3, and no activity against clas I/II HDACs.500 The 
present disertation demonstrates the exacerbation  of  RSV infection in the context  of a 
highly selective  SIRT1 inhibitor and in  CD11c+-specific Sirt1 KO  mice, suggesting that 
during viral infection,  SIRT1  promotes a  protective immune environment linked to 
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autophagy  within  DCs.  These  observations  may  be especialy important, as  most severe 
exacerbations in asthma and COPD are asociated with viral infections.5 
Ongoing and Future Studies 
Adjuncts can boost the immunogenicity of vaccines, but careful selection is required, 
as common alum-based adjuvants  have shown to  promote a  Th2-asociated response522, 523 
that is frequently asociated  with vaccine-enhanced  disease symptoms.108, 524 Based  on the 
CD11c-specific Sirt1 KO  mouse experiments, Sirt1-deficient  CD11c+ DCs  drive a  Th2 
response in the airways and in restimulated T cels isolated from infected animals. Perhaps 
SIRT1 activating compounds, such as  Resveratrol (natural)  or  SRT1720 (synthetic), could 
serve as  potential adjuvants in combination  with a  RSV vaccine to stimulate a  more  Th1-
driven response that would prevent disease exacerbation. These SIRT1 activators could also 
be considered as  part  of a preventative regimen for immunocompromised  or 
immunodeficient individuals. Of  note,  Resveratrol treatment  of  RSV-infected  human cel 
lines  has  been shown to  downregulate IL-6  production and to partialy inhibit  RSV 
replication.525, 526 Curently, we are administering daily Resveratrol by oral gavage to BALB/c 
mice, which have been infected with RSV Line 19. Given the augmented pathology observed 
in RSV-infected mice receiving EX-527 (Figure 4.1), but the protection from emphysema or 
asthma in mice treated with SRT1720,490, 491 we predict that the Resveratrol treatment group 
wil clear  RSV  beter  by  8  dpi,  displaying litle to  no  mucus  hyperplasia and insignificant 
levels  of lung inflammatory cytokines, as compared to  RSV-infected controls.  While the 
exact influence of Resveratrol on SIRT1, and other posible biological targets, is not clearly 
understood,486,487 the results  of  our study  would  be the first to  describe the efects  of the 
compound on the immunopathology of RSV infection.  
SIRT1 has been shown to induce autophagy as a protective mechanism during stres 
conditions, including hypoxia, oxidation, and the accumulation of toxic/unfolded proteins, 
in a wide range of cel types.382, 527, 528 We have demonstrated that in the absence of SIRT1, 
and therefore adequate levels  of autophagy, DCs  upregulate caspase  3/7 activity (i.e. 
apoptotic pathway) compared to control cels (Figure 3.10), yet these Sirt1-deficient cels do 
not perish in a greater proportion or rate (Figure 3.11). Interestingly, a separate study also 
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observed the upregulation of caspase-3 without cel death during CD8+ T cel proliferation in 
vivo.529 This prompts the  question  whether  other SIRTs are compensating for the lack  of 
SIRT1 to maintain organele function, such as the mitochondria-specific SIRT3, 4, or 5. For 
example, we observed evidence of mitophagy in RSV-infected Cre- BMDCs, yet could not 
identify autophagocytosed,  damaged  mitochondria in Sirt1-deficient  Cre+ BMDCs (Figure 
3.9). Studies have already shown that mitochondrial SIRTs can serve as tumor suppresors 
and  promoters, regulate fatty acid  metabolism,  promote cardiac and  HSC stres resistance, 
and reduce ROS levels, al of which encompas functions of SIRT1, too.378, 530 Specificaly, 
SIRT3 has been reported to regulate mitochondrial biogenesis via interactions with PGC1α 
(also a SIRT1  partner), inducing  mitochondrial  DNA replication and synthesis  of 
mitochondrial  proteins.531 Likewise, another study  has  described  how  SIRT3  orchestrates 
antioxidant machinery, as wel as mitophagy, via the mitochondrial UPR during proteotoxic 
stres.532 Perhaps, mitochondrial SIRTs are capable of regulating mitochondrial homeostasis 
during RSV infection, in such a way as to mitigate the necesity of mitophagy in context of 
SIRT1/autophagy dysfunction. In that regard, it would be wise to study the efects of Sirt1-
deficiency on the expresion and activity of the other six mammalian SIRTs, in an efort to 
identify any overlapping sirtuin functions in the realm of DC biology.  
Since virus-induced endoplasmic reticulum (ER) stres is a  known  biological 
response,232 RSV-infected Sirt1f/f-CD11c-Cre+ DCs may be experiencing altered ER stres due 
to Sirt1 deficiency, contributing to the  observed caspase-3 activity. Preliminary studies 
suggest that Sirt1-deficient BMDCs and  pulmonary  DCs experience exponentialy greater 
ER stres than control cels in response to RSV infection, as indicated by the upregulation in 
gene expresion  of several  UPR  proteins including Xpb1s, which  mediates IRE1α signaling 
(Appendix 3A-C).356 UPR induction was verified with Tunicamycin, an N-acetylglycosamine 
transferase inhibitor that  halts glycosylation  of  newly synthesized glycoproteins, leading to 
the accumulation of unprocesed proteins in the ER.357 At two observed time points, Sirt1-
deficient  BMDCs expresed greater mRNA levels  of UPR proteins in response to 
Tunicamycin (Appendix  3D). These  data are similar to the ER stres changes we  noted in 
autophagy-deficient AECs, in  which  mRNA expresion  of Edem1 and Xbp1s were 
significantly elevated in RSV-infected Lc3b-/- AEC cultures 12 hpi.533 Thus, Sirt1 deficiency 
 90 
and autophagy deficiency paralel each other both in terms of DC cytokine reduction (Figure 
3.3A) as  wel as in the case  of  UPR activation, providing further evidence in support  of a 
reciprocal relationship between SIRT1 and the autophagy pathway. 
Studies  have shown that co-treating  macrophages  with chemical  ER stresors and 
TLR3/4 activators significantly enhanced IFNβ production in an  XBP1s-dependent 
manner.534 TLR ligation was also reported to suppres PERK signaling while simultaneously 
activating and re-routing  XBP1s signaling away from canonical  UPR targets toward 
proinflammatory genes.535, 536 Thus, protein-folding homeostasis may be suppresed in favor 
of innate immune signaling. Additionaly, SIRT1 and inflammatory cytokine protein levels 
were  upregulated  upon  TLR4 signaling in a  human  monocyte cel  model  of endotoxin 
tolerance.537 Once endotoxin tolerance  developed,  SIRT1  promoted epigenetic 
reprogramming to  downregulate cytokine  production,  by  binding to the Tnfa and Il1b 
promoters and recruiting the anti-inflammatory NFκB subunit, RelB.537 As SIRT1 has been 
atributed  with the atenuation  of  ER stres,5, 388, 389 including the inhibition  of XBP1s 
transcriptional activity,387 it is plausible that SIRT1 initialy promotes UPR-related signaling 
until the stresor (e.g.  pathogen) is eliminated, at  which  point the deacetylase curbs 
proinflammatory signaling to restore  homeostasis. Therefore, the  observed  upregulation  of 
ER stres protein gene expresion in Sirt1-deficient DCs may be downstream of incomplete 
TLR-activation, which leads to unsuccesful upregulation of inflammatory cytokines in the 
absence of SIRT1. If proven corect, this would be another example of SIRT1’s coordination 
of multiple pathways (e.g. UPR and inflammatory) with an ultimate goal of celular survival 
and maintenance.  
In relationship to pulmonary disease, IRE1α-mediated XBP1s-activation may sustain 
the amplified ER calcium stores frequently observed in inflamed airway mucosa,538 as well as 
the excesive IL-13-driven mucus  production  observed in alergic airway  disease.77 While 
further genetic studies are  necesary to firmly  determine  whether and  how  observed  UPR 
activation contributes to inflammatory airway disease, we can speculate that ER stres may at 
least  partialy explain  why viral infection, such as  RSV,  often instigates  or exacerbates 
baseline pulmonary pathology.5 Future experiments should addres the mechanistic details of 
the  potential interaction(s)  of the  UPR and  SIRT1  during  RSV infection—such as  UPR 
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transcription factors  directly regulating  SIRT1 expresion—both in  DCs and the  primary 
targets of RSV infection, the AECs. 
Chapter  1 addresed how  both autophagy and  SIRT1  participate in  nutritional 
toggling, efectively promoting celular homeostasis. At the organismal level, Atg5-/- or Atg7-/-
mice sufer from systemic  nutritional  deficiency and extreme glucose deficits,  while Sirt1-/- 
mice are susceptible to  hepatic steatosis,  mitochondria  dysfunction, and metabolic 
ineficiency upon dietary chalenge.421, 539, 540 Awarenes of energy imbalance likely evolved as 
a  mechanism  by  which eukaryotes detected and eliminated  pathogens through autophagy, 
while SIRT1’s enzymatic requirement for NAD+ intimately links it to a cel’s metabolic state. 
Additionaly, SIRT1 interacts with nutritional pathways to mediate celular energy balance, 
including the represion  of  mTOR and the activation  of FOXO transcription factors to 
induce autophagy.380, 394 These interactions were verified in our studies by the upregulation of 
Foxo3 gene expresion alongside Sirt1 expresion in RSV-infected DCs (Figure 3.2A), which 
coincided with an increased autophagosome formation (Figure 3.4, Figure 3.8). 
Given these relationships, a fascinating line  of research  would  be investigating the 
metabolic alternations—and  how they relate to  SIRT1—within DCs specificaly infected 
with RSV, and how these hinder or facilitate DC activation and APC function. Metabolic 
regulation and cel signaling are tightly and ubiquitously linked with immune responses, and 
wel studied in the case of lymphocyte biology.541-543 DCs must adjust their extracelular and 
intracelular environments as they migrate to nutrient or oxygen-deficient sites, and during 
the reprogramming that  proceeds after inflammatory stimulation (i.e. resulting from a 
microbial invader). Recent studies have indicated that  TLR signaling-mediated  metabolic 
reprogramming facilitates  DC  maturation and antigen  presentation.544, 545 TLR stimulation 
and Type 1 IFN drive the switch from oxidative phosphorylation to aerobic glycolysis, a les 
eficient  but  more rapid energy-producing  proces, similar to the  Warburg efect in cancer 
cels.544, 545 This shift is likely required to  meet the energy  demands  of activated  DCs, thus 
preventing  premature  death in  order to sustain an immune response. Additionaly, 
dysregulated  mTOR  or  AMPK activity (inhibitor and activator  of autophagy, respectively, 
Figure 1.2) impairs  DC  development and  maturation, suggesting the significance  of a 
metabolic checkpoint in promoting DC function. As SIRT1 can directly suppres mTOR via 
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deacetylation,  our results suggest that SIRT1  deficiency  does  not  dramaticaly alter this 
metabolic checkpoint, as  we  did  not  observe atenuated  DC  maturation  or  development. 
However,  SIRT1  dysfunction negatively afected  downstream  DC cytokine  production, 
which greatly impacted the resultant adaptive immune response.  
 Furthermore, Chapter 1 explored how viruses exploit baseline celular proteins and 
pathways to their  own advantage, such as for progeny  propagation  by commandeering 
autophagosomal machinery or ER function. What aspects  of  DC  biology does RSV 
counteract  or seize control  over in an atempt to  prevent detection?  While autophagy 
significantly heightens PRR activation, via  delivery  of viral antigen to endosomal  TLRs, 
other cytoplasmic PRRs participate in RSV detection. Do RLRs or NRLs interact with stres 
pathways, like the previously  described  TLR asociation  with the  UPR,  or  metabolic 
pathways? The plausibility of SIRT1 influencing a majority of these changes is quite high as 
it targets such a tremendous aray of proteins, and this could be preliminarily addresed with 
a  microaray panel analysis  of immune and  metabolic  pathways. Moreover, it  would be 
highly  waranted to investigate SIRT1’s activity at the epigenetic level, as it was initialy 
described as a  histone  deacetylase and obviously influences cytokine  production and cel 
stres survival in this manner.537, 402 
In conclusion, this thesis  work suggests crucial roles for the  protein  deacetylase 
SIRT1 in innate immunity, specificaly in the activation of DCs through autophagy during 
RSV infection. Our findings also suggest  SIRT1  may  be  particularly  beneficial  during an 
antiviral immune response to limit  pathological  outcomes. Thus,  SIRT1  pharmacological 
activators, such as Resveratrol, may serve a part in preventative therapies aimed at fortifying 
weak  or insuficient immunity in  RSV-susceptible  patients.  Likewise, the creation  of 
adjuvants containing SIRT1-activating components may be beneficial, as this could facilitate 




Appendix 1:  TNFα-stimulated NFκB-dependent IL-6  production is  amplified in the 
presence  of  a  SIRT1 inhibitor. Previous  work  has revealed that  SIRT1 can  block immune and 
inflammatory proceses, including cytokine production in APCs,390, 484 due to its transcriptional represion 
of  NFκB (RelA/p65) via  deacetylation.408 TNF signals via the  NFκB  pathway to  promote IL-6 
production; of note, NFκB binds the promoter region of IL-6. This particular experiment indicates that in 
the presence of SIRT1 inhibition and TNF stimulation, DCs are stil proficient at cytokine production. 
Therefore, lack of SIRT1 does not intrinsicaly impair cytokine gene transcription and secretion. Likewise, 
this  data suggests that  under certain stimuli,  SIRT1-inhibited  DCs  do  not rely  on autophagy-mediated 
proceses, and that instead,  blockade  of  SIRT1 leads to cytokine  production  driven  by increased  NFκB 
acetylation. Experimental Design: WT BMDCs cultured from BL6 mouse legs were treated ±1 µM EX-
527 30 min prior to stimulation with 10 ng/mL recombinant TNFα for 2, 4, or 6 hours. Cytokine gene 

























































Appendix 2: Sirt1-deficient BMDCs have attenuated proteins levels of LC3 in response 
to RSV infection. During autophagosomal formation, the protein LC3 is proteolytically 
modified into LC3II, which is recycled upon vesicular maturation.  The chemical Bafilomycin 
blocks this  maturation event  by inhibiting lysosomal acidification and thus autophagosome-lysosome 
fusion.244 Protein analysis  of  RSV-infected  DCs isolated from Sirt1 conditional  KO  mice shows lower 
levels  of  LC3II/I,  LC3II, and  LC3I  protein ratios, suggesting a  decrease in autophagy flux. This  data 
verifies our  previous  observation that Sirt1-deficient  BMDCs  undergo low levels  of autophagy  during 
RSV infection (Figure  3.8). Therefore, it is  posible that  SIRT1 enhances autophagy,  but it is  not 
absolutely required. Experimental Design: (A) BMDCs isolated from Sirt1f/f-CD11c-Cre mice were treated 
with Bafilomycin 30 min prior to infection with RSV Line 220 for 2 h. After cel harvest and protein lysis, 
samples were run on SDS-PAGE gels (20 µg per wel), folowed by membrane transfer and immunoblot 
for LC3I/II or β-actin.  UN  =  untreated controls. (B) Protein levels were  quantified as  mean band 
fluorescence intensity ratios over β-actin  protein band intensity, compared to  uninfected cels.  Data are 
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